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GENERAL INTRODUCTION 
Bovine immunodeHciency-like virus (BIV) is a lentivirus of cattle which was 
first isolated and described over 20 years ago (1). BIV has been postulated to cause 
immunodeficiency, based on the clinical signs in the cow infected with the first 
(R29) isolate of BIV (1) and on the genetic relationship of BIV to the human 
immunodeficiency virus (HIV) (2). Until recently, however, little research has been 
done to examine this hypothesis. Recent studies on neutrophil function, T cell 
subsets, and lymphocyte blastogenesis in BIV infected cattle have found subtle 
alterations in neutrophil function (3), and decreased (4) or increased (3) lymphocyte 
blastogenesis. There is one report describing possible depletion of CD4+ T cells in 
infected animals (5). The primary target cell for most lentiviruses is, however, the 
macrophage (6). Although the cell tropism for BIV is not fully known, data 
presented in this dissertation and elsewhere (7) indicate that monocytes and 
macrophages are one of the cells infected by BIV. As described in the literature 
review in this dissertation, macrophage functional abnormalities have been found in 
HIV infection and in cats infected with the related feline immunodeficiency virus 
(FIV). Therefore, we examined macrophage function in cattle infected with BIV, as 
well as the direct effects of BIV virus on normal macrophages in vitro. 
Dissertation Organization 
The first chapter of this dissertation is an overview of known macrophage 
function defects in lentivirus infection. The second chapter is a manuscript on 
macrophage function and virus isolation in a group of cattle experimentally infected 
with the R29 isolate of BIV. This paper also describes the functional abnormalities 
found when normal monocytes are treated in vitro with supernatants from BIV 
infected cells. The third chapter is a manuscript describing the isolation of the active 
factor, the BIV Gag protein, from these cell supernatants. Finally, the fourth 
chapter is a manuscript describing an unusual lymphosarcoma in one of the BIV 
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infected cattle, which may have been associated with BIV infection. The dissertation 
concludes with a general sunmiary. Also included are four appendices which contain 
more specific information on the macrophage function assays developed during this 
dissertation project, data describing how monocyte random migration, chemotaxis, 
and antibody-dependent cell-mediated cytotoxicity change during 5 day culture of 
monoqrtes in vitro, unpublished observations on in vitro infection of macrophages 
with BIV, and the development of a sandwich ELISA for the detection of BIV p26 
antigens. 
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LITERATURE REVIEW: 
THE EFFECTS OF LENTIVIRUSES ON MACROPHAGE FUNCTION 
The lentivirus genus of the Retroviridae (1) contains a group of complex viruses 
which tend to cause slow, progressive disease. Members of the genus include the 
human, feline, and simian immunodeficiency viruses (HIV, FIV and SIV, 
respectively), bovine immunodeficiency-like virus (BIV), caprine arthritis-encephalitis 
virus (CAEV), equine infectious anemia virus (EL\V), and ovine visna/maedi virus. 
The immune system plays a dual role in the pathogenesis of lentiviral disease; while 
the immune system can control and limit virus replication, it is also involved with the 
production of disease. For some lentiviruses, notably CAEV and visna, proliferation 
of immune cells and damage to tissues by chronic immune stimulation is an 
important mediator of disease (2). In contrast, the immunodeficiency-causing 
lentiviruses progressively destroy immune function. 
Macrophages are target cells for all known lentiviruses (2); however, the 
relationship between macrophages and the immunodeficiency viruses is far more 
complex than simply that of virus and target cell. The macrophage is a cell with 
many roles. Macrophages are important in both innate and acquired immunity; their 
functions range from roles in tissue repair and basic "housekeeping" functions such as 
synthesis of complement components, to antigen presentation in a specific immune 
response. They phagocytcse foreign invaders, secrete an array of cytokines, and may 
have a role in anti-tumor immunity. It should not, then, be surprising that 
macrophages have multiple roles in lentivirus infection. Macrophages harbor virus, 
secrete cytokines which influence virus replication, and may aid in controlling 
lentivirus infection by antigen presentation. In turn, however, lentiviruses may affect 
macrophage activities ranging from cytokine secretion to killing of bacteria. 
This review will describe how the immunodeficiency viruses (HIV, FIV, SIV 
and BIV) affect macrophage functions, and what impact these effects might have on 
disease. Most research has focused on HIV infection; related lentiviruses such as 
4 
SIV, FIV and BIV will be discussed where information is available. An initial 
overview will describe the role of macrophages in the pathogenesis of human 
immunodeficiency virus infection, and the evidence that macrophages are infected 
with lentiviruses. Subsequent sections will discuss the effects of virus on macrophage 
precursors; on cell surface molecules; on chemotaxis, antibody-dependent cell-
mediated ototoxicity (ADCC), phagocytosis, and oxidative metabolism; on antigen 
presentation and cytokine secretion; and on macrophage roles in tissue damage and 
repair. Molecular mechanisms have been discovered for some of these areas; for 
others, the science is still at a descriptive level. Finally, the hypothesis that defects in 
macrophage function are the result of chronic macrophage activation will be 
discussed. 
Virus Structure and Replication 
The lentiviruses are complex in both structure and genetic organization. These 
100-130 nm enveloped viruses contain a central capsid surrounding a nucleoprotein 
complex of viral mRNA and nucleocapsid protein (1,2). A matrix protein is 
associated with the viral envelope (1,2). The lentivirus genome is a 9-10 kB single 
stranded RNA, flanked by 3' and 5' long terminal repeat (LTR) sequences in the 
proviral form (2). The structural genes for all lentiviruses include the gag, pol and 
env genes (1,2). The gag gene is transcribed and translated into a polyprotein 
precursor. Gag, which is proteolytically cleaved during the formation of mature 
virions into the virus capsid, nucleocapsid, and matrix proteins, as well as variably 
present small proteins of undetermined function (1,2,3). The processing of the Gag 
proteins appears to be quite complex: for BIV, a number of protein cleavage 
products ranging from 10 to 53 kDa have been shown or predicted to be present 
during processing of Gag (4). 
The Pol precursor is cleaved into the reverse transcriptase, integrase, and 
protease (1). The env gene is transcribed, translated and modified into a glycosylated 
envelope protein which is cleaved into a large hydrophilic surface protein, and a 
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smaller hydrophobic transmembrane protein (1,2). In addition, lentiviruses contain 
gene segments coding for the positive regulatory proteins Tat and Rev (1,2). Other 
regulatory proteins are also present in lentiviruses; however, they may not be present 
in all members of the lentivirus genus. For example, the BIV genome does not 
appear to contain any region coding for the negative regulatory factor Nef, but does 
contain an open reading frame (ORF) for Vif and two unique ORFs known as W 
and Y (5). 
Macrophage Infection by Lentiviruses 
Numerous papers have documented that monocytes and macrophages can be 
infected by HIV, SIV, and FIV in vitro (1,6-15). Although there are no published 
reports which describe the full range of leukocytes infected by BIV, BIV does appear 
to infect macrophages (16,17). Factors influencing macrophage infection with HIV 
and SIV include the strain of virus, the donor source of monocytes/macrophages, 
and the state of macrophage activation (8,11,18,19), Macrophages appear to be the 
primary cell type infected with HIV and SIV in tissues (20,21). The percentage of 
HIV infected macrophages, as well as the amount of HIV RNA per cell, appears to 
be much higher in the tissues than in blood (2,20). In particular, productive infection 
of the macrophage appears to be higher in the tissues (2,20). In AIDS patients, while 
a very low percentage of blood monocytes appear to be infected (less than 0.001%), 
1-10% of the brain microglia, 10% of lymph node dendritic cells, and 10-50% of 
alveolar macrophages may be infected with HIV (20). In children, even higher levels 
of macrophage infection may be seen, particularly in the lungs (22). Macrophages 
from tissues other than the lung have not been studied as intensively; however, 
Kupffer cells are infected in some patients (23), and infected macrophages have 
been detected in the brain (24,25), placenta (26) and bone marrow (24). Related 
cells such as dendritic and Langerhans cells also appear to be infected (20,27,28), 
although some have questioned these results (29). Tissue macrophages that have 
been infected with HIV in vitro include peritoneal macrophages (13) and Kupffer 
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cells (23). 
In vitro studies have demonstrated that monoqrtes are easier to infect and 
produce greater amounts of HIV and SIV virus after differentiation into 
macrophages (8,11,18,19). Although most researchers agree that blood monocytes in 
some patients can be infected with HIV, it is still somewhat controversial whether 
monocytes are infected in ail individuals. Some studies have found infected 
monocytes in most patients examined (30,31); however, others have found monocyte 
infection in few patients (32,33). A similar uncertainty exists for FIV infection (34). 
Some of this variability may be due to the technique used to detect virus. Many early 
experiments (32,33) used LTR and/or env gene primers in PCR detection of 
retroviral DNA. Recent reports (31,35) have, however, found that gag gene primers 
are most successful at amplification of HIV DNA from monocytes. Many of the 
earlier papers may have missed monocyte infection through the use of LTR primers, 
which are very poor at detecting HIV infection in monocytes. Furthermore, it seems 
unlikely that monocyte infection would be present in only a minority of patients. 
Recent studies demonstrate that macrophage tropism is necessary for infection of the 
brain and lungs by HIV or SIV (36,37), and macrophage infection in the lung and 
brain is common (20). Tissue macrophages are primarily replenished by the 
differentiation of blood monocytes; therefore, the most likely route for tissue 
invasion of macrophage-tropic viruses would be by infected monocytes. 
Overview: the Role of Macrophages in the Pathogenesis of Disease 
Of the immunodeficiency viruses, the pathogenesis of disease is most 
completely known for HIV, SIV infection in macaques appears to parallel HIV 
infection in humans and has been used as a model for AIDS (36,38); less is known 
about FIV. BIV has not yet been proven to cause any major immunodeficiency. In 
the initial studies of HIV infection, the CD4+ T cell appeared to be the only 
leukocyte important in disease. AIDS was seen as a simple progression: after a 
period of latent infection of T cells and no clinical signs, latent virus became 
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activated, and caused destruction of T cells, leading to clinical immunosuppression 
and death. More recent views of HIV infection are more complex, and the latent 
period is seen as a time when virus replication continues to occur at a high rate (39), 
damage to the immune system and decline in CD4+ cell numbers is progressive, and 
virus-immune system interactions may influence the length and possibly the outcome 
of disease (21). Macrophages appear to be involved, either directly or indirectly, in 
many aspects of pathogenesis. 
Macrophage influence on virus variants 
The initial interaction of HIV with the immune system occurs with an 
inoculum containing multiple virus variants. Some of these variants appear to be 
suppressed during or before transmission, or by the initial immune response (40-43). 
There is, in fact, intriguing evidence that macrophage tropic variants may be initially 
selected (40-43). HIV variants have been classified by several phenotypic 
characteristics, including cell tropism, the ability to induce syncytia in T cells, and 
rate of replication (40). While these characteristics may not be absolute (44), they 
have been useful in characterizing changes in virus populations over time. In general, 
the non-syncytium-inducing (NSI) variants share the characteristics of low rate of 
virus replication and the ability to replicate in macrophages as well as T cells. The 
syncytium inducing (SI) isolates, in contrast, have a higher replication rate, are more 
cytopathic, and have lost the ability to replicate well in primary macrophages 
(40,42,43). There is evidence that, although both SI and NSI variants are transmitted, 
SI (non-macrophage tropic) variants are generally eliminated early in the interaction 
with the immune system (40,43). As a result, in asymptomatic patients, NSI variants 
predominate (40,43). The important factor in the restriction of virus types during 
transmission is believed to be their macrophage tropism (40,42,43). In support of this 
theory, there is evidence from one patient that, when SI variants are monocytotropic, 
they do survive during the initial stages of disease (40). 
The selection pressure causing this initial expansion of NSI viruses and 
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suppression of SI viruses is unknown. At least 2 theories have been proposed. One 
theory is that the early immune response clears the NSI variants, due to some 
phenolic characteristic of the viruses (42). HIV is less <ytopathic in macrophages 
than in T cells (45) and may, therefore, survive longer in macrophages while the 
immune system is still intact. In some culture systems, although HIV buds on the cell 
surface from T cells, it buds into intracytoplasmic vacuoles in macrophages (20). If 
this in vitro pattern reflects the pattern of virus budding in vivo, virus within 
macrophages might be hidden from the immune system. Others believe that, 
although this explanation may be true for a minority of cases, in most cases the virus 
tropism results from the initial cell type the virus encounters (43). According to this 
theory, except during intravenous transmission, the virus first encounters mucosal or 
placental macrophages and only the macrophage tropic isolates can replicate in these 
cells. Which theory, if either, is correct has yet to be determined. 
Macrophages in early HIV infection 
During the early period after infection, HIV and SIV viruses disseminate 
throughout the body (21), probably carried mainly by monocytes (36,37). Virus 
upregulation of macrophage adhesion molecules may occur, and could influence the 
invasion of tissues by infected cells (46). In the subclinical phase of infection, the 
immune system is apparently intact and both antibody and cell-mediated responses 
against HIV (or SIV) are seen (21,38). In cases where high neutralizing antibody 
titers exist, macrophage- T cell interactions or dendritic cell - T cell interactions may 
be an important means of virus transmission between cells (29,43). There is evidence 
that dendritic cells pulsed with HIV can infect T cells (29); whether the virus is 
spread by infection of the dendritic cell or simply uptake and sequestration of the 
virus (with consequent spread to T cells) remains to be determined. In this particular 
experiment, no budding of viruses from dendritic cells was seen (29). 
During this early period, changes in macrophage-related cells in the lymph 
node occur. Follicular dendritic cells appear to be slowly destroyed or depleted 
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(20,21). Other, more subtle changes in macrophage lineage cells may also occur. 
Masutani et al (47) report a reduction in "adult T cell leukemia derived factor" 
(ADF), a cytokine secreted primarily by dendritic cells in the paracortex of the 
lymph node and macrophages in the sinuses (but not by follicular dendritic cells). In 
one AIDS-related complex (ARC) case, and several AIDS cases, lymph nodes were 
depleted of ADF-producing cells, particularly in the paracortical regions. This 
phenomenon did not appear to be due to cell death, as other proteins produced by 
paracortical dendritic cells did not appear to be affected. 
Most overt defects in macrophage activity do not appear until late in disease, 
and macrophages may be activated during the early stages of infection. Cytokine 
derangements, particularly increased cytokine secretion, appear to be present in HIV 
(48-51) and SIV (52) infection. Recent evidence indicates that HIV replication may 
be occurring at high rates even early in disease (39). Virus replication at this time 
may be driven by increased levels of cytokines, particularly tumor necrosis factor 
(TNF) and interleukin-1 (IL-1), and again, the macrophage may be involved (21,53-
59). HIV appears to induce release of some cytokines from macrophages (53-57), 
and these cytokines may feed back on the virus to further upregulate (or, in some 
cases, downregulate) replication (21,58,59). 
Some authors speculate that, during this asymptomatic period, macrophages 
may also be involved in the selective loss of memory T cells and loss of proliferative 
responses to recall antigen, through inappropriate antigen presentation; antigen 
presentation without appropriate second signals may cause apoptosis in T cells 
responding to recall antigens (43). 
Late stage disease 
As disease progresses, viral variants emerge which have greater tropism for T 
cells than for macrophages (40,43). Although the macrophage tropic variants 
continue to be present at the previous levels, an increase in virus replication is seen. 
Most of the new viruses are SI variants, with high tropism for T cells and much less 
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for macrophages (40,43). A precipitous drop in CD4+ cell numbers eventually 
begins, and full-blown AIDS develops (21). During this time, macrophage infection 
may influence the clinical manifestations of disease. Encephalitis, myelopathy, 
pneumonitis, and lymphadenopathy are closely linked to virus replication in tissues, 
and tissue pathology is often correlated with HIV or SIV gene expression in 
macrophages (22,36,60), A high percentage of infected alveolar macrophages may 
contribute to the high incidence of lymphoid interstitial pneumonia in children with 
HIV (22). In SIV infection, giant cell pneumonia and granulomatous encephalitis 
have been associated with infection of tissue macrophages (36,35). Within the brain 
and lung, virus infection may influence the secretion and synthesis of a number of 
macrophage products which are able to cause tissue damage, including qrtokines, 
eicosanoids, and reactive oxygen and nitrogen metabolites (61). Many of the 
macrophage defects discussed in this review appear at this late stage, although some, 
particularly cytokine derangements, may occur earlier. The following sections will 
examine the known effects of the immunodeficiency viruses on macrophage function 
in more detail. 
Effects on Macrophage Precursors 
HIV,SIV,FIV 
AIDS patients, SIV infected macaques, and FIV infected symptomatic cats all 
have hematologic abnormalities including lymphopenia, anemia, neutropenia and 
thrombocytopenia (62-68). Depressed monocyte numbers have not been reported 
(69); however, selective decreases in the monocyte and granulocyte bone marrow 
precursor CFU-GM (as well as in the erythrocyte precursor BFU-E) have been 
reported following infection with either SIV or HIV (62,63,65,66). One study also 
found a selective suppression of some precursor populations when bone marrow 
cultures from HIV-infected individuals were grown in vitro (65). While some 
hematopoietic precursors were produced in normal numbers, the differentiation of 
granulocyte/macrophage precursors and erythrocyte precursors was selectively 
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suppressed in cultures from HIV infected individuals (65). In HIV infection, the 
numbers of circulating monocyte precursors also appear to be depressed during the 
asymptomatic stage of infection (62). In contrast, abnormalities in bone marrow 
culture have not been found in asymptomatic FIV infected cats (64) or in one 
symptomatic cat (68), even though hematologic abnormalities have been seen in 
infected cats. Additional studies, particularly in symptomatic cats, are needed to 
confirm the finding that bone marrow culture is normal in FIV-infected cats. 
The mechanisms for virus suppression of hematopoietic precursors have not 
been fully determined. Possible mechanisms for suppression include altered cytokine 
production, cellular or viral inhibitory factors, the killing of infected precursors by 
leukocytes, or infection of precursors resulting in death or metabolic alterations (63). 
There is little evidence that altered levels of cytokines are responsible for the bone 
marrow abnormalities seen in HIV and SIV infection. There is one report that the 
HIV transactivating protein, Tat, induces bone marrow macrophages to secrete the 
inhibitory cytokine transforming growth factor jS (TGF-/3) (70). The relevance of this 
finding to the in vivo situation remains to be determined. Decreases in IL-3 and 
granulocyte-monocyte colony stimulating factor (GM-CSF) have also been postulated 
to be involved in the bone marrow abnormalities; IL-3 and GM-CSF stimulate the 
production of macrophages and neutrophils, and IL-3 and GM-CSF levels have been 
reported to be depressed in AIDS patients (62,71). Nevertheless, physiologic doses of 
IL-3 and GM-CSF do not appear to be able to restore normal bone marrow function 
(62,63). In some cases, high in vitro doses of GM-CSF and IL-3 appear to increase 
CFU-GM colony formation from SIV and HIV infected individuals (62,63); however, 
the relevance of such high doses of cytokines to in vivo hematopoiesis is unknown. 
Infection of hematopoietic precursors does not appear to be responsible for 
bone marrow suppression by HIV or SIV (62,63,67). Although there have been 
reports of infection of precursors by large doses of HIV (72), these cells do not 
appear to be a major reservoir of virus in vivo (62). SIV virus also appears to be 
harbored in bone marrow stromal macrophages and not in hematopoietic precursors 
12 
(67). In SIV (66) and HIV infections (62), increased virus burden in macrophages 
and peripheral blood mononuclear cells (PBMC) has been correlated with 
suppression of bone marrow precursor colony formation. In vitro studies have, 
however, also demonstrated virus-mediated depression in CFU-GM without evidence 
of latent or productive infection (62,63). Lympho<ytotropic HIV IIIB (which is 
unable to infect macrophage precursors) can also suppress colony formation of CFU-
BM (73). It appears, therefore, that a virus product, or a virus-mediated change in 
cellular products, may be responsible for the selective suppression of bone marrow 
precursors in HIV and SIV infection. A good candidate is the envelope glycoprotein, 
gpl20. In one study, pre-incubation of virus with antibodies to gpl20 neutralized the 
effect of HIV virus on macrophage precursors (62). Recombinant gpl20/gpl60 also 
appears to suppress colony formation (74). One hypothesis is that the effect of 
gpl20/gpl60 is to induce apoptosis in some hematopoietic precursors (62). No 
evidence has yet been published to support this hypothesis. 
Very little is known about the cause of bone marrow suppression in cats 
infected with FIV. There is one report of serum from a symptomatic FIV positive cat 
suppressing autologous CFU-GM but not CFU-GM from healthy FIV negative cats, 
suggesting that some serum substance was acting only on CFU-GM infected or 
altered by FIV (68). This serum factor was not identified further. 
Macrophage Cell Surface Molecules 
HIV 
Macrophage surface molecules have mainly been examined in HIV infection. 
Cell surface expression and/or function of MHC class I and II molecules, as well as 
macrophage Fc, complement and mannose receptors, may be altered by infection 
with HIV. These molecules will be discussed in conjunction with defects in antigen 
presentation (MHC molecules), chemotaxis (complement receptors), and phagocytic 
function (Fc and mannose receptors). The expression of CD4 on macrophages also 
appear to be decreased after infection (75-77), although not all groups could confirm 
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this finding (78). CD4 is of interest primarily due to its role in infection of 
macrophages by HIV. One study compared neutral glycolipids (which are involved in 
cell interactions, differentiation, and binding microorganisms) in promonocytic U937 
cells infected by HIV or the human T lymphotropic virus (HTLV I) (79). Although 
infection by the oncovirus HTLV I affected ganglioside concentrations in the cell 
membrane, there was no difference in any glycolipids examined after HIV infection. 
Integnns 
Integrins play roles in both macrophage migration and cell interactions such 
as cell cytotoxicity and antigen presentation. They also appear to be involved in 
macrophage recognition of opsonins leading to phagocytosis (80): increased 
expression of integrins is associated with increased phagocytic ability for 
Staphylococcus aureus and Escherichia coli (46). Increased expression of integrins has 
also been postulated to be involved in the transport of HIV into the brain by 
infected macrophages (46). 
Integrins are cell surface molecules composed of an alpha and a beta chain. 
The 3 integrins Mac-1 (CR3), LFA-1, and p150,95 (CR4) share a common jS chain 
(CD18); however, each has a unique alpha chain. Mac-1, LFA-1, and pl50,95 are all 
found on monocytes and macrophages, and levels of LFA-1 and p150,95 appear to 
be influenced by infection with HIV. Expression of the alpha subunit of p 150,95 
(CDllc) is increased by HIV infection (80,81). Levels of the LFA-1 a subunit, 
CDlla, have also been found to be increased on monocytes or macrophages from 
HIV-infected patients by some (81,82) but not all (80,83) groups. In contrast, 
although increased (81) or decreased (83) expression of the Mac-1 a subunit CD lib 
has been found, most evidence indicates that CD lib is not altered by HIV infection 
(78,80,84). The effect of HIV on the common ^ subunit, CD18, is also still 
controversial, as both unchanged (80) and increased (82) levels have been reported. 
The effect of HIV infection on integrin levels on promonocytes, but not 
promyelomonocytes, may be similar to the effect on mature monocytes and 
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macrophages. In one study, promonocytic lines (U937 and THP-1) chronically 
infected with HIV had increased CDllc expression (as well as CD15, HIA-DR, and 
HIA-DQ), when compared to uninfected cells (85). Promyelomonocytic lines, in 
contrast, had decreased levels of CDllc and HLA-DR (but increased CD15 and 
HLA-DQ) (85). Petit et al (86) have confirmed that chronically infected U937 cells 
upregulated pl50,95, as well as CDlla and CD18. 
It appears, therefore, that the integrin molecules pl50,95 and LFA-1 but not 
Mac-1 are upregulated by HIV infection of monocytes, macrophages, and 
promonocytic cell lines. The mechanisms for integrin upregulation or suppression by 
HIV have not been determined. Integrins are upregulated during monocyte 
activation; therefore, one explanation for the increased expression of integrins is that 
HIV infection is causing monocyte activation. Some evidence exists in support of this 
hypothesis, including possible changes in FcIII receptors (87) and the increased 
secretion of some cytokines after HIV infection (48-51,54,88). 
Chemotaxis 
HIV 
A decrease in monocyte chemotaxis has been well documented in HIV-
infected individuals (69,89-91). In AIDS patients, a significant decrease in 
chemotactic migration, with preservation of normal random migration, was first 
reported by Smith et al (69). A marked reduction of migration in response to all 
stimuli examined - C5a, the bacterial peptide fMLP (N-formyl-methionyl-leucyl-
phenylalanine), Giardia lamblia, and "lymphocyte-derived chemotactic factor" - was 
seen. In this study, patients with persistent lymphadenopathy also had depressed 
chemotactic function, intermediate between normal controls and AIDS patients, 
although this was not significant at the P < 0.05 level. Poli et al (90) also observed a 
selective depression of chemotaxis with no other monocyte abnormalities in a group 
of 17 AIDS patients. These results have been confirmed in other studies (89,91). 
Martin et al (92), however, found that different defects in chemotaxis and random 
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migration may be found, depending on the method used to study migration (blind 
well chamber or migration under agarose), and the stage of disease. The results of 
Martin et al (92) are plausible, as migration under agarose depends more on cell 
adhesiveness than does migration in blind well chambers and, may, therefore, be 
affected differently by HIV infection (92). Unfortunately, this study used 
unfractionated mononuclear cells rather than monocytes, and differences in 
monocyte percentages between patients may have affected the migration results. 
Therefore, although the study is intriguing, it remains to be confirmed using purified 
monocytes. 
The suppression of migration in blind well chambers appears to be a result of 
interaction with viral proteins and is not necessarily a result of infection of the 
macrophage. Decreased migration appears to be mediated through an interaction 
with the envelope and/or transmembrane proteins of HIV (89,91). Chemotaxis can 
be broken down into stages of ligand binding, monocyte polarization toward a 
stimulus, and movement. The defect in chemotaxis appears to be mediated at the 
step of ligand binding and/or monocyte polarization. In one study, in vitro infection 
of monocytes with HIV suppressed monocyte polarization to a stimulus, with 
significant suppression first seen 24 to 36 hours after infection (89). This effect could 
be duplicated by the addition of gpl20 to monocytes, with similar kinetics observed 
(89). From these results, it appears that the initial binding of virus to monocytes 
during infection was able to mediate a decrease in migration. A concurrent decrease 
in fMLP receptor and C5a receptor staining was seen, suggesting that decreased 
ligand binding had resulted in the suppression of chemotaxis (89). These researchers 
also found an upregulation of class II MHC molecules with the same kinetics as the 
depression in chemotaxis, indicating that the effect on migration might be part of a 
general activation of the cell. 
The HIV capsid protein, p24, does not appear to have any effect on monocyte 
migration (91); however, the transmembrane glycoprotein (gp41) appears to mediate 
a decrease in monocyte polarization (91). Recombinant gp41, as well as serum 
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fractions of 25-30 kDa from the serum of asymptomatic HIV infected individuals and 
AIDS patients, was able to suppress migration. The effect of 25-30 kDa serum 
fractions could be abolished by the addition of an antibody to gp41; it appears that a 
breakdown product of gp41 was responsible for the suppression observed. 
Retroviral transmembrane peptides related to the murine leukemia virus 
pl5E protein have also been found in the serum of oncovirus infected and cancer 
patients (93) and may mediate immunosuppression (94,95). The pl5E peptide is 
derived from a highly conserved portion of the retroviral transmembrane protein, 
and related sequences are present in HIV (96). Some researchers have suggested 
that these pl5E-related peptides may mediate the decreased chemotaxis seen in 
AIDS (94,97). The breakdown product of gp41 found in the above experiment does 
not, however, appear to be the pl5E related portion of the protein (91). Some serum 
samples in this study also contained small (less than 25 kDa) factors which were 
serologically related to pl5E and which could inhibit monocyte polarization. These 
small factors were, however, detectable only in the serum of HIV seronegative 
homosexual individuals and did not appear to be related to gp41 (91). In addition, a 
study using synthetic transmembrane peptides from HIV and other retroviruses has 
shown that, although many retroviruses contain pl5E-reIated peptides able to 
suppress monocyte polarization, the HIV peptide has a relatively weak effect (94). It 
therefore appears that, although pl5E related peptides may contribute slightly to 
suppression of chemotaxis, they are unlikely to be the major factor responsible for 
the effect. Other gp41 breakdown products and/or gpl20 appear to be more likely 
candidates for the role. 
SIV,FIV,BIV 
Macrophage chemotaxis does not appear to have been examined in SIV or 
FIV infections. Onuma et al (16), however, found suppressed chemotaxis in 3 BIV 
infected calves, early in infection. We were not able to confirm this result. In our 
studies, BIV infection status had no effect on random or chemotactic migration of 
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monocles isolated from infected animals (17), There was, however, a significant 
enhancement of both random and chemotactic migration when monocytes were 
treated in vitro with BlV-containing cell supernatants or recombinant p26 Gag 
protein (98). 
Antibody-Dependent Cell-Mediated Cytotoxicity 
HIV 
There are few reports on antibody-dependent cell-mediated cytotoxicity 
(ADCC) of monocytes in HIV infected individuals. In an early report on 17 ARC 
and 9 AIDS patients, ADCC was normal, although monocyte chemotaxis was 
suppressed in the same patients (90). Two, more recent, reports have found 
depressed monocyte ADCC either in AIDS patients or in macrophages infected with 
HIV in vitro (84,99). Bender et al (84) found depressed ADCC in a group of AIDS 
patients. In addition, relatively high concentrations of serum (25 or 40%) from these 
individuals were able to suppress ADCC of normal mononuclear cells. A criticism of 
this study was that it used unfractionated mononuclear cells rather than isolated 
monocytes. ADCC is also a function of NK cells, and it is unclear from the methods 
whether NK cell or monocyte ADCC was being measured. In another study, 
however, monocyte derived macrophages (MDM) infected in vitro also had reduced 
ADCC against 5 leukemic target cell lines (99). This study is, perhaps, the most 
convincing evidence that monocyte ADCC mediated killing may be suppressed by 
HIV. Molecular mechanisms for the suppression of ADCC have not been 
determined. 
SIV,FIV,BIV 
ADCC function does not appear to have been examined in SIV or FIV 
infected macrophages. Monocyte ADCC does not appear to be affected in BIV 
infected animals; however, treatment of monocytes in vitro with BIV resulted in a 
dose-dependent decrease in ADCC function, consistent with the effects seen with 
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HIV (17). Infection of the monocyte was not necessary for this suppression. 
Killing of Bacteria and Fungi 
HIV 
Killing of bacteria and fungi by macrophages is a complex process. Most 
extracellular organisms are killed by phagocytosis, in conjunction with reactive 
ojQTgen metabolites, reactive nitrogen intermediates, and/or lysosomal enzymes, 
cytokine upregulation of macrophage activity is necessary for effective killing of 
some bacteria, particularly intracellular bacteria which can multiply within un-
activated macrophages. A number of opportunistic infections, as well as disseminated 
infections by pathogens, are common in AIDS; therefore, a wide variety of organisms 
have been used in studies on bacterial and fungal killing by macrophages. Although 
it has not been found that HIV-infected macrophages have a generalized defect in 
killing of all microorganisms, defects have been found in the killing of some specific 
microorganisms. 
The most general studies have examined the final result of the macrophage 
interaction with a microorganism: the reduction in colony counts when bacteria or 
fungi are mixed with HIV-infected macrophages. Defective killing of Aspergillus 
fumigatus by monocyte-derived macrophages (MDM) from HIV infected children 
(100), and of Candida by macrophages from HIV infected adults (99,101) have been 
observed. Killing of Leishmania donovani does not appear to be affected by HIV 
infection; however, Leishmania is a more difficult organism to kill than Candida 
(101). An early study reported that the killing of Toxoplasma gondii by macrophages 
from infected patients was also unchanged (101). In contrast, Murray et al found that 
killing of T. gondii and Chlamydia psittaci by macrophages from AIDS patients was 
defective when using unstimulated macrophages; however, these macrophages were 
able to kill bacteria normally after they were activated with interferon 7 (102,103). 
Murray et al (103) suggest that the defects found in macrophage killing of bacteria 
are simply a reflection of decreased stimulation by interferon 7 in vivo] however, 
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other studies using macrophages infected in vitro or treated with purified HIV 
proteins do not support this hypothesis (99,104-106). 
Another study also found that HIV is able to affect macrophage-mediated 
killing of 71 gondii by a different mechanism involving interferon (107). This 
particular study also illustrates the complications which may occur in killing assays. 
Killing of T. gondii by interferon stimulated macrophages was found to be depressed 
in HIV infected, asymptomatic individuals and patients with lymphadenopathy. No 
defects in killing were, however, seen in unstimulated macrophages. On closer 
examination, the "defect" in interferon-stimulated macrophages appeared to be due 
to an enhancement in growth of Toxoplasma when the organisms were stimulated 
with interferon (107). A similar phenomenon has been demonstrated for other 
microorganisms; the growth of mycobacteria may also be stimulated by interferon 
(108). In the Toxoplasma study, it appeared that increased interferon was reaching 
intracellular organisms in the HIV-infected macrophages. Any interferon-mediated 
enhancement in macrophage activity could not, apparently, overcome the increase in 
the replication rate of the toxoplasma organisms. The authors speculate that an 
increase in the number of interferon receptors on macrophages from HIV infected 
patients was responsible for allowing additional interferon to reach the organisms 
(107). They did not, however, stain directly for interferon receptors. 
Studies of phagocytosis do not suffer from such complications, as they 
measure a single aspect of bacterial killing, and often use killed organisms or inert 
particles. As a result, however, they present a more limited picture of the effects of 
HIV on bacterial killing. A number of studies have examined phagocytic function of 
HIV infected macrophages directly. The simplest studies have examined the 
ingestion of latex beads or red blood cells, to determine if there are any general 
defects in macrophage internalization of particles. Most of these studies have found 
no defects in phagocytosis of inert, non-opsonized particles (84,90,101) even when 
antibody-mediated phagocytosis was impaired in the same study (84). A more 
sophisticated approach is to examine the internalization of pathogenic or 
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nonpathogenic organisms, with or without opsonization by antibody or complement. 
Such studies have found defective phagocytosis of a variety of organisms, particularly 
fungi (100,101-106). Crowe et al demonstrated defective phagocytosis of opsonized 
Candida albicans or T. gondii by monocyte derived macrophages infected with the 
Ba-L or DV strains of HIV, or a clinical monocyte-tropic isolate (104). Using 
monocyte-derived macrophages from HIV-infected children, Roilides et al (100) also 
found defective phagocytosis oi Aspergillus fumigatus. Alveolar macrophages from 
HIV-infected adults appear to have phagocytic defects against Pneumocystis carinii 
(105) and Cryptococcus neoformans (106). 
No common mechanism has been found for these defects in phagocytosis. 
One common factor, however, may be that only adherent macrophages have their 
phagocytic activity altered by HIV infection. All of the studies which found 
phagocytic defects used macrophages grown in adherent systems; in a single study 
using monocyte derived macrophages cultured in Teflon bags and infected with a 
monocyte tropic isolate of HIV, no phagocytic (or killing) defects of macrophages 
against a variety of bacteria could be found (78). 
A variety of cell surface receptors appear to be involved in the phagocytic 
defects found, with different receptors involved for different organisms. Changes in 
antibody Fc receptor expression do not, however, appear to be involved in 
phagocytic defects. Fc receptors on macrophages do not appear to be downregulated 
in HIV infection (78,84,87,109). These results do not, however, exclude the 
possibility of impaired receptor function with normal surface expression. 
The decreased phagocytosis of Pneumocystis carinii appears to be due to 
impaired mannose receptor function (105). The apparent mechanism is competition 
of HIV proteins with Pneumocystis for binding to the mannose receptor. The HIV 
gpl20 envelope protein (but not the p24 Gag protein) was able to suppress binding 
of macrophages to either mannose-rich proteins or to Pneumocystis (105). 
Interestingly, gpl20 was also able to inhibit phagocytosis of Cryptococcus neoformans, 
but not by competition for a receptor (106). Gpl20 depressed macrophage 
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internalization, but not binding, of C neofonnans by an unknown mechanism (106). 
The gp41 transmembrane protein has not been tested for effects on phagocytosis. 
Retroviral pl5E-related transmembrane peptides have been tested only against 
opsonized chicken erythrocytes; in this system, no effect on monocyte phagocytosis 
was seen (97). 
In the Candida albicans system, the mannose receptor does not appear to be 
involved in phagocytosis; instead, the defect in phagocytosis of this organism appears 
to result from the downregulation of the Mac-1 integrin (complement receptor CR3) 
by HIV (104). Most other studies have found no differences in CR3 levels in HIV 
infection (78,80,84); however, these studies used different virus isolates, or 
macrophages from infected patients, and do not necessarily invalidate these results. 
Bender et al (91) found defective clearance of antibody or complement opsonized 
inert particles by the reticuloendothelial system in AIDS patients, although no 
decrease in the number of Mac-1/CR3 receptors was seen (84). The clearance of 
unopsonized particles was not, however, affected. It is possible that a direct effect of 
HIV infection of macrophages in vitro is to depress Mac-1/CR3 expression, but that 
cytokine or other interactions in vivo result in normal expression, with impaired 
function. HIV proteins were not tested in the C. albicans system. 
As different receptors are used for the phagocytosis of different organisms, it 
is difficult to determine whether a generalized phagocytic defect exists for HIV 
infected macrophages. Most evidence, to date, indicates that it does not. In addition, 
there are some organisms for which killing defects have been found, but phagocytic 
function does not appear to be impaired. One study found normal phagocytosis, in 
spite of a defect in killing Candida pseudotropicalis, when monocyte-derived 
macrophages were infected in vitro with the monocyte-tropic HIV-JRFL isolate (99). 
Another study using macrophages from AIDS and LAS (lymphadenopathy syndrome) 
patients also found normal phagocytosis with concurrent defects in killing of bacteria 
(49). As described above, the growth of Toxoplasma gondii may be stimulated in HIV 
infected macrophages, after interferon stimulation (107). It is not known whether 
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phagocytosis is also affected for T. gondii. Furthermore, mycobacteria may also grow 
better in HIV-infected macrophages than in uninfected macrophages. Newman et al 
found that macrophages infected in vitro with the Ba-L isolate of HIV, then 
superinfected with Mycobacterium avium or Mycobacterium tuberculosis had increased 
intracellular growth of the bacteria in HIV infected macrophages, as well as cytokine 
derangements (54). It is not known whether interferon receptors were altered in this 
study. Unfortunately, a nearly identical study was unable to confirm these results 
(110). Currently, the best evidence indicates that phagocytic defects exist for 
internalization of some organisms, and that killing of other organisms may be 
impaired by mechanisms other than a defect in phagocytosis. 
SIV,FIV,BIV 
There have been relatively few studies examining macrophage phagocytosis or 
microbial killing by macrophages infected with Antiviruses other than HIV. These 
studies are, however, particularly interesting as most of them have been done at very 
early stages of infection. This is generally not possible with HIV. Phagocytic function 
of macrophages from SIV infected monkeys does not appear to have been measured; 
however, peritoneal macrophages of cats in an early stage of infection with FIV were 
found to have increased antimicrobial activity against Toxoplasma gondii (111). 
Macrophages from FIV infected cats, therefore, appear to be activated for microbial 
killing during early infection. The equivalent studies from very early stages of 
infection are not available for HIV; however, results from macrophages infected with 
HIV in vitro show suppressed rather than increased antimicrobial activity. 
Unlike FIV, BIV does not appear to activate macrophages for killing of 
microorganisms in vivo. In one study, BIV infection suppressed the ingestion of latex 
beads by monocytes from 2 of 3 infected calves (16). In BIV infected calves followed 
for 2 years PI, we also found a tendency for a decrease in phagocytosis of opsonized 
Staphylococcus aureus early during infection. This was not, however, statistically 
significant, and did not persist after the first 8 months PI. In contrast, monocytes 
23 
treated in vitro with supematants from BlV-infected cells (17) or with recombinant 
BIV Gag (98) had a significant dose-dependent increase in S. aureus ingestion. The 
discrepancies between these in vivo and in vitro results remain to be resolved. It is 
likely, however, that the enhancement of phagocytosis was not seen in vivo because 
monocytes were not exposed to high levels of the BIV Gag proteins. In addition, 
monocyte exposure to immunosuppressive cytokines, or other viral interactions, may 
have masked any effect of low levels of BIV Gag proteins in vivo. 
Therefore, it appears that FIV and BIV do not affect antimicrobial activity as 
reported for HIV. While HIV appears to decrease antimicrobial activity in vivo and 
in vitro, FIV infection in vivo and BIV in vitro both appear to enhance antimicrobial 
activity (17,98,111). Few studies have examined macrophage fiinction in lentiviruses 
other than HIV, and it may be dangerous to generalize from a small number of 
studies. Currently, however, suppression of antimicrobial activity does not appear to 
be a general effect of lentiviruses. 
Reactive Oxygen Metabolites 
HIV 
Reactive oxygen intermediates are involved in the killing of some 
microorganisms. Increases in oxidative metabolism may, however, also produce tissue 
damage, particularly lung damage (112). Currently, there does not appear to be a 
consensus on whether oxidative metabolism is affected in AIDS. Suppression of the 
oxidative burst in HIV-infected individuals (101), no effect (49,101,113), or an 
increase in the oxidative burst with the progression to AIDS (112,114) have all been 
reported. Some of the variability in results may result from differences in patient 
selection. Some investigators have found that the effect on oxidative metabolism 
varies with the stage of infection. In one study, increased macrophage 
chemiluminescence was found in a group of asymptomatic, HIV antibody positive, 
antigen negative patients, with depressed chemiluminescence in the antigen and 
antibody positive group (114). Some studies, particularly earlier studies (49,101), may 
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also have been influenced by the presence of occult bacterial or fungal infection in 
HIV-infected patients. In one group of asymptomatic, HIV positive individuals which 
were carefully screened to rule out the presence of occult lung infections, alveolar 
macrophages from HIV-infected individuals were found to have an enhanced 
spontaneous release of superoxide anion (112). This upregulation was transient, and 
suggestive of macrophage activation (and possibly exposure to interferon 7) in vivo. 
Interestingly, the oxidative response of monocytes to interferon may be 
altered in some HIV infected individuals. Pennington et al (113) found normal O2-
production in the monocytes of AIDS patients; however, treatment of these patients 
with recombinant interferon 7 suppressed rather than enhanced the respiratory burst 
of isolated monocytes. Furthermore, treatment of monocytes from infected patients 
with interferon in vitro resulted in a heterogeneous set of responses (unlike that of 
monocytes from normal controls). Interferon treatment consistently enhanced the 
respiratory burst of monocytes from normal controls; however, monocytes from 3 
AIDS patients responded to interferon with an increased respiratory burst, and 3 
with a decreased respiratory burst. This result is consistent with a study 
demonstrating that the HIV p24 protein may alter the pattern of gene activation 
after interferon treatment (115). No obvious patient factors explained the variability 
between individuals. 
It appears that in vitro studies may be necessary to clarify the results obtained 
from monocytes infected in vivo; however, few in vitro studies on monocyte oxidative 
metabolism have been done. One study found normal chemiluminescence in infected 
macrophages; however, the authors infected macrophages with a monocyte tropic 
isolate (Ba-L) which had been grown in mitogen-stimulated peripheral blood 
lymphocytes (PBLs) (78). Growth of virus in mitogen-stimulated PBLs is known to 
restrict virus tropism in favor of exclusively lymphocyte-tropic strains, and may, 
therefore, have resulted in alterations in virus characteristics. Other investigators, in 
contrast, have demonstrated a suppression of the monocyte respiratory burst (101). 
While it is unknown whether gpl20 or gp41 affect the monocyte oxidative burst, the 
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pl5E retrovirus consensus sequence, CKS-17, is able to suppress the respiratory burst 
in monocytes (97). Further research is necessary to resolve the discrepancy between 
the in vivo results, demonstrating a possible upregulation in oxidative metabolism, 
and the in vitro results demonstrating no change or a suppression in the respiratory 
burst. It is possible that the direct effect of HIV virus is to suppress oxidative 
metabolism, but that in vivo interactions modulate this response. 
SIVyFIVyBIV 
Oxidative metabolism does not appear to have been measured in FIV or SIV 
infection. Monocyte chemiluminescence was measured in 3 calves infected with BIV 
and found to be suppressed; unfortunately, the statistics attempt to compare 
variability between samples in 1 calf to variability in a group of 5 control calves (16). 
Therefore, this study must be repeated before conclusions can be drawn. 
Reactive Nitrogen Intermediates 
Data on the reactive nitrogen intermediate (RNI) system is currently sparse; 
however, envelope gpl20 appears to increase the production of nitric oxide in 4 day 
old (but not 0 day old) monocyte-derived macrophages (116). This effect could not 
be suppressed by the addition of soluble CD4, indicating that it was not mediated by 
binding of gpl20 to the usual cellular receptor CD4. The sugar mannan and a yeast 
chelate did, however, abolish the effect. The effect of gpl20 on the RNI system, 
therefore, appears to be mediated through the macrophage mannose receptor. 
Antigen Presentation 
HIV 
Antigen presentation by HIV infected macrophages is difficult to measure 
well. Tests are complex, and generally involve the depletion of monocytes from T 
cell cultures, the isolation and infection of purified monocytes, the presentation of an 
antigen by monocytes, and the measurement of lymphocyte proliferation in the 
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reconstituted cultures. While a number of studies have examined aspects of antigen 
presentation, such as the levels of MHC class II molecules or accessory cell function 
(<ytokine secretion and levels of co-stimulatory molecules), fewer papers have 
examined the antigen presenting ability of macrophages more directly. One early 
paper examined the proliferative response to Candida, in 2 sisters with identical 
MHC class II types. One sister was infected with HIV, and did not have a 
blastogenic response to Candida. When macrophages from this patient were mixed 
with lymphocytes from her sister, blastogenesis to Candida was suppressed (117). 
Other papers have reported antigen presentation or accessory cell function defects in 
dendritic cells and macrophages (43), or monocytes (118,119) from asymptomatic, 
HIV infected individuals, patients with LAS, and AIDS. HIV may also have an effect 
on actual numbers of antigen presenting cells. Numbers of antigen presenting (but 
not phagocytic) macrophages in the duodenum appear to be reduced, as determined 
by staining for specific markers (120). 
Some experiments have determined the effect of HIV infection in vitro on 
macrophage accessory cell function. Many of these have measured mitogen-induced 
blastogenesis. Although mitogen-induced blastogenesis does not require antigen 
presentation by macrophages, macrophages are necessary in this system for their 
costimulator function. Lacroix et al (121) tested the accessory cell function of 
monocyte derived macrophages infected with HIV (IIIB strain) at 2 or 7 days PI. 
They measured the proliferation of autologous T cells depleted of monocytes, and 
reconstituted with either uninfected or infected monocyte derived macrophages. Both 
phytohemagglutinin (PHA) and anti-CD3 antibody stimulated blastogenesis were 
suppressed when HIV-infected macrophages were tested; the addition of uninfected 
monocytes restored normal proliferative responses. Live virus was necessary for this 
effect. IL-1 and interleukin-6 (IL-6) were found to be low in the culture 
supematants; addition of IL-1 and IL-6 to the cultures partially restored 
blastogenesis in response to PHA stimulation. Although unchanged or elevated, 
rather than depressed, levels of IL-1 have been found in infected macrophages 
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(50,51,56,88,122-125), these studies were all performed in isolated macrophages and 
not stimulated mononuclear cell cultures. It is possible that interactions between T 
cells and HIV-infected macrophages result in lower than normal levels of IL-1 than 
direct stimulation of these macrophages by Q'tokines or lipopolysaccharide. Other 
experiments have confirmed that antigen presentation ability and IL-1 synthesis 
declined concurrently in HIV infected macrophage hybridomas (126) and U937 
promonocytic cells (118). In U937 cells, the suppression of antigen presentation 
coincided with the period of virus proliferation; however, simple addition of virus to 
T cells (at the level present in the cultures) did not suppress blastogenesis (118). 
Although decreased levels of cytokines may be partially responsible for the 
suppression of PHA blastogenesis (118,121), addition of cytokines does not appear to 
restore blastogenesis in anti-CD3 stimulated cultures (121). The authors of one study 
speculate that HIV infection also inhibits function of macrophage Fc receptors (121). 
Macrophage Fc receptors are necessaiy in the anti-CD3 system, to cross-link the 
antibody which stimulates CD3 receptors. Other studies have not demonstrated a 
decrease in Fc receptors I and 11 (78,84,87,109); however, function of the Fc receptor 
might be affected without an effect on expression (121). It is unclear whether such 
inhibition of Fc receptors has any relevance to antigen presentation in vivo. 
In addition to cytokine production, antigen presentation ability of 
macrophages depends on a number of factors, including expression of class II 
molecules and other accessory molecules. A number of studies have stained infected 
macrophages for class II MHC antigens. Decreased (83,86,114,126,127), unchanged 
(77) and increased (46,82,85,101,112) class II expression have been reported. Sperber 
et al (126) report a concurrent decline in class II MHC expression, IL-1 production 
and antigen presentation ability of HIV infected macrophages. Some of the 
discrepancy in the results of different studies may result from measuring class II 
expression at different stages of infection. Alterations in tytokine release by HIV and 
subsequent effects on class II expression might also be seen in some systems. Even 
with isolated promonocytic cells, the effects of HIV on class II expression are still 
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controversial. Decreases in class II molecules, with no change in class I expression, 
were seen in U937 cells infected with HIV in one system (86); however, increases in 
class II molecules on these cells (HLA-DR, DQ), under similar conditions, were 
found by others (85). 
Other accessory molecules involved in antigen presentation have rarely been 
studied; one study found decreased expression of accessory molecules (B7/BB-1) 
after infection with HIV (43). Additional research will be needed to resolve the 
discrepancies, and determine if changes in class II or B7 expression are involved in 
antigen presentation defects in AIDS. It is quite likely that a combination of changes 
in cytokine secretion, class II MHC, and other macrophage molecules are 
responsible for defective antigen presentation by HIV infected macrophages. 
Finally, one caveat must be observed in determining the effects of HIV on 
antigen presentation: in many experiments, it is difficult to determine whether 
antigen presentation by macrophages is defective, or whether antigen presentation is 
normal and macrophages are actively inhibiting T cell proliferation by some other 
mechanism. In at least one case, adherent cells seemed to actively inhibit T cell 
proliferation; depletion of adherent cells from cultures enhanced blastogenesis (119). 
This inhibitory activity was not due to virus production, and appeared to be due to a 
heat-labile protein. Other experiments have implicated prostaglandin £3 (PGE2) in 
the inhibition of lymphocyte proliferation by HIV-infected macrophages. 
Prostaglandin £3 downregulates the immune system, and there are reports of 
possible prostaglandin dysregulation in AIDS (49,101,114). Although plasma levels of 
PGE2 appear to be normal, their synthesis and release by unstimulated monocytes 
may be altered (49,101). One paper describes a prostaglandin-mediated suppression 
of lymphocyte blastogenesis and lymphokine activated killer (LAK) cell induction in 
asymptomatic, HIV positive individuals (114). In this experiment, monocytes from 
AIDS patients actively suppressed blastogenesis and LAK cell induction with 
lymphocytes from normal individuals (114). Addition of indomethacin to block 
prostaglandin synthesis, and IL-2, restored levels to normal. 
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SIV,FIV,BIV 
There appear to be no studies which have examined the effect of lentiviruses 
other than HIV on macrophage antigen presentation ability. 
Effects on Cytokine Release 
HIV,SIV,FIV 
In addition to their roles in antigen presentation, cytokines are involved in 
regulating monocyte chemotaxis, phagocytic function, and ADCC. Cytokines may also 
act on infected cells to inhibit or activate virus replication (21,58,59,128,129). Some 
cytokines which may be altered by HIV infection include TNFa, IL-1, lL-6, and GM-
CSF. 
Tumor necrosis factor a 
TNFa, IL-1, IL-6, and GM-CSF are cytokines which have been documented 
to activate HIV. TNF appears to be particularly important in AIDS, as it both 
activates HIV and mediates some of the physiologic effects of infection (21,58). A 
number of studies have measured the release of TNFa, as well as other cytokines, 
from HIV infected macrophages. Some early research determined that the 
spontaneous or LPS-stimulated production of TNFa from monocytes or macrophages 
of AIDS patients was increased (25,130,131). A problem with many of these studies 
was the inclusion of patients with secondary infections or tumors (25,130). In a study 
of AIDS patients without active secondary infections (132), there were no differences 
in serum TNF, or TNFa from cultured PBMC, when mean values were compared to 
normal controls. The AIDS patients did, however, have increased variability within 
the group; 10 of 26 patients had TNF levels that were either higher or lower than 
the control mean by greater than 2 standard deviations. In a study using alveolar 
macrophages from asymptomatic, HIV positive individuals, there was a trend toward 
lower TNF production than controls when macrophages were stimulated with 
lipopolysaccharide (LPS) (133), It is somewhat difficult to directly compare this study 
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to the others, as a different macrophage ^e, as well as a different stage of disease, 
were studied. In fact, Lathey et al (48) have recently found that TNF produced from 
blood monocytes may vary with the stage of disease. They report that TNFa (as well 
as IL-1/8) levels appear to be upregulated in asymptomatic HIV infected individuals, 
with a loss of this upregulation as the patients progress to AIDS. In asymptomatic 
individuals, TNF mRNA was present in unstimulated monocytes, although TNF 
production after stimulation with LPS was not different from controls. From this 
data, it appeared that monocytes were activated in asymptomatic individuals. TNF 
mRNA was, however, no longer found in unstimulated monocytes from AIDS 
patients. The monocytes from AIDS patients still appeared to be receiving activation 
signals (i.e., neopterin levels were increased); however, they no longer appeared to 
be reacting to the signals for increased TNF production. Unfortunately, this study 
also includes patients with secondary diseases, as well as some individuals on AZT. 
A more direct approach, which eliminates the problem of concurrent 
infections, has been to examine TNF levels in monocytes infected in vitro. Conflicting 
results have also been found, with this approach. While some studies (53,54,56,88) 
have found that infection with HIV is able to induce spontaneous and/or elevated 
production of TNFa in vitro from peripheral blood monocytes, others (123-125,134) 
find no elevation of TNF production after infection. Some studies which find no 
effect of infection have used monocyte tropic strains of HIV such as Ba-L; however, 
the specifics of virus challenge, including virus strain and multiplicity of infection, as 
well as the length of macrophage culture and method of cytokine stimulation may 
account for the conflicting results. It is also possible that the timing of some of these 
studies may have missed the burst of TNF production, 2 to 6 hours after infection, 
found by Merrill et al (56). Merrill et al (56) found that binding of HIV to CD4 
mediated an increase in TNFa production with no requirement for productive 
infection of the macrophage. More recently, Clouse et al (57) have confirmed that 
recombinant gpl20 is able to induce TNF production by binding to macrophages. 
Studies using HIV infected promonocyte cell lines have also found increases in TNF 
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after HIV infection (122,135). There is, therefore, evidence that the initial 
perturbation of the cell membrane through gpl20 binding to CD4 results in a 
transient burst of TNFa production. Nevertheless, a consensus has not been reached 
on whether HIV infection changes the levels of TNF production from monocytes in 
vivo. Increased TNF in vivo may also result from macrophage activation from 
concurrent infections, or influences of other cytokines. 
Tumor necrosis factor production from macrophages has also been studied in 
both FIV infection and SIV infection, but not BIV. In rhesus macaques, TNF levels 
have been found to be significantly increased in asymptomatic animals, then 
depressed after the progression to AIDS (52). This correlates well with the situation 
found in HIV infected humans by Lathey et al (48). In asymptomatic FIV infected 
cats, although no abnormalities in serum TNFa were found for the first 6 months 
post-infection, increased levels of TNFa production were found after vaccination or 
challenge with FeLV, compared to cats not infected with FIV (136). 
Interleukin 1 
IL-1 production appears to be increased by infection with HIV, although, 
again, this may vary with the stage of disease. Although not all reports agree 
(90,124), most studies have found increases in IL-1 production, in either the 
asymptomatic stage only (48), or in patients with persistent lymphadenopathy (49) or 
AIDS (49-51). Furthermore, Herman et al (50) have found that AIDS patients have 
both increased IL-1 activity and an increase in IL-1 inhibitors. This study may 
explain why some studies using thymocyte proliferation assays to test for IL-1 have 
not found increased levels of IL-1. In the thymocyte proliferation assays, the 
biological response would appear to be a response to normal levels of IL-1, due to 
the masking of high IL-1 levels by the IL-1 inhibitors. Infection of monocyte derived 
macrophages (54,56,88) or promonocyte lines (122) has also been found to increase 
IL-1 production and/or IL-1 specific mRNA. The studies in immature monocyte 
lines may, however, simply reflect a slight maturation of promonocytes induced by 
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infection with HIV, which might increase the cell capacity to make IL-1 (122). 
Interleukin 6 
Although fewer studies have examined IL-6 than IL-1 or TNF, IL-6 levels 
have usually been found to be normal (48,55) in HIV infected patients. IL-6 levels 
from macrophages infected in vitro have, however, been found to be elevated in 
some studies (54,88). Inactivated, noninfectious HIV (55) has also been found to 
induce IL-6 from mono(7tes, although plasma IL-6 levels were found to be nonnal in 
asymptomatic, ARC, or AIDS patients in the same study (55). It is possible that local 
levels of IL-6 are high in tissues with active HIV infection, but that this is not 
reflected in serum IL-6 levels. A recent study found that the HIV transactivating 
protein Tat was able to induce IL-6 (but not GM-CSF or TNFa) from peripheral 
blood monocytes (137). Tat has also been reported to induce TGF/3 by bone marrow 
macrophages (70). 
Other cytokines 
A few studies have examined the production of other cytokines from infected 
macrophages. Alveolar macrophages from HIV infected patients were found to 
spontaneously release small amounts of GM-CSF, and to produce greater than 
normal levels of GM-CSF after LPS stimulation (138). This phenomenon appears to 
support the theory that macrophages from HIV infected patients are activated in 
vivo. Others have found that monocytes infected in vitro with HIV then stimulated 
with LPS produced elevated levels of IL-8 (139) but normal M-CSF (139). In a 
nonadherent system, depressed levels of M-CSF were found (88). Relatively few 
studies have investigated interferon production from macrophages; however, one 
intriguing study found that cultured macrophages infected with HIV and then treated 
with a double stranded RNA or with 2 different RNA viruses were able to produce 
normal levels of TNFa, IL-1, IL-6, or interferon 0 (IFN/3), but did not produce IFNa 
(124). The block appeared to be at the transcriptional level. There have been reports 
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that the interferons may have antiretroviral activity against HIV (128,129,140); 
suppressed secretion of interferon might interfere with this effect. Others have also 
found that monocytes and PBMC from infected patients have a decreased ability to 
secrete IFNa or to produce IFNa mRNA (130,141,142). 
Finally, there is one report that treatment of monocytes with the HIV p24 
core protein alters the response of monocytes to interferon y (115). Recombinant 
p24 treatment of the THP-1 monocyte line inhibited the normal interferon induced 
increase in HLA-DR (class II MHC) and qrtochrome b mRNA. 
Alterations in the cytokine response to pathogens 
Increased or decreased cytokine levels may be in themselves interesting, 
particularly when the cytokine is one like IL-1 or TNF which can cause side effects 
such as fever or muscle wasting, or reveal macrophage activation present in vivo\ 
however, the primary importance of cytokines is their regulation of the inunune 
response to pathogens. One particularly interesting study, rather than examining 
(^okine levels in HIV, examined the cytokine response to Pneumocystis carinii by 
HIV infected macrophages (143). Monocyte derived macrophages were infected with 
HIV Ba-L, then exposed 10-14 days later to P. carinii. Uninfected macrophages had 
higher levels of IL-1 and TNFa than HIV infected macrophages when treated with 
P. carinii. IL-6 levels were comparable in infected and uninfected macrophages. 
Similar results were seen in response to a Pneumocystis 95-115 kDa gpA protein 
(143). This cytokine response may be organism specific; in contrast to the results 
with P. carinii, HIV infected macrophages appear to secrete increased IL-ljS and 
TNFo! when coinfected with Mycobacterium avium (143). 
Macrophage Roles in Tissue Repair 
Most studies of macrophages infected with HIV have examined immune 
functions and not basic macrophage "housekeeping" functions. A few interesting 
studies have, however, examined the role of infected macrophages in tissue repair. 
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Some researchers have found that HIV infected macrophages adhere to and spread 
on extracellular matrix proteins more efficiently than control cells (144). While this 
effect may be partly due to increased expression of integrins, other mechanisms also 
appear to be involved. Dhawan et al (144) found that when equal numbers of HIV 
infected and control monocytes were cultured on a matrix of basement membrane 
proteins, the HIV infected macrophages not only spread faster, but also degraded 
the matrix around them. These macrophages expressed p24 and were productively 
infected. Culture fluids from HIV infected macrophages contained higher levels of a 
92 kDa metallogelatinase than supernatants from control macrophages. Neutral 
proteases such as metallogelatinase are secreted by tissue macrophages and are 
involved in remodeling, wound healing, and inflammation; this report (144) raises 
the possibility that healing functions may be affected by HIV infection of 
macrophages. 
Another report has implicated macrophages in the glomerulosclerosis 
observed in some AIDS patients (145). Increased mesangial cell proliferation and 
matrbc synthesis may be responsible for this phenomenon, and Mattana et al report 
that supernatants from HIV-serum treated macrophage cell line (J774.16) 
significantly increased mesangial cell synthesis of collagen (145). This experiment 
used a macrophage cell line, and is rather vague on the patient profiles; this study 
should be confirmed using tissue or monocyte-derived macrophages. 
Finally, macrophages in AIDS patients may be less able to participate in 
normal hemostasis. Tissue factor is a macrophage cytokine that initiates the 
coagulation protease pathway, and may, therefore, be involved in wound healing. 
Tissue factor production from LPS stimulated monocytes was found to decrease with 
the progression to AIDS (48). 
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The Activation Hypothesis 
Do HIV effects on macrophage activation eventually result in a state of generalized 
macrophage dysfunction? 
In an early review on monoQrte function in AIDS patients, Estevez and Sen 
(101) suggested that monocytes and macrophages might become chronically activated 
by HTV, which would eventually lead to generalized defects in macrophage function. 
In this theory, infected macrophages are activated and produce proinflammatory 
cytokines (e.g. IL-1, TNF, and IL-6). These cytokines lead to increases in virus 
concentrations, and increased stimulation of macrophages, T and B cells. Eventually, 
negative feedback mechanisms on the macrophage would result in a concurrent 
increase in PGE2. The permanently activated state, they hypothesized, would lead to 
a state of macrophage dysfunction. This hypothesis is consistent with some but not 
all of the in vivo data presented above. Some evidence suggests that macrophages 
are activated by HIV infection: this evidence includes increases in integrin (and 
possibly MHC class II) expression, increased IL-1 and possibly TNF synthesis, and 
increased reactive nitrogen metabolism. Interestingly, Allen et al (87) have shown an 
increased expression of FC7RIII on freshly isolated monocytes from AIDS patients. 
Expression of this receptor is correlated with macrophage activation or 
differentiation. The theory cannot, however, account for some changes in 
macrophage function in cells infected by HIV in vitro, including suppression of 
antigen presentation, phagocytosis, and ADCC. The chronic activation hypothesis 
predicts an initial increase in these parameters, followed by suppression. Activation 
for these functions is not, however, seen in macrophages infected in vitro. Therefore, 
although a unifying theory for the multiple effects of HIV on macrophage function is 
attractive, the activation hypothesis cannot explain all of the defects in monocyte 
function seen following HIV infection. This does not preclude the possibility that 
HIV causes macrophage activation; however, individual virus proteins or fragments 
(particularly gpl20 and gp41, but also Tat) also appear to have direct suppressive 
effects on macrophage functions. 
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Summaiy/Conclusions 
It is apparent that HIV is able to affect macrophage function, mainly to the 
detriment of the immune system. The formation of monocyte precursors in the bone 
marrow, as well as function of mature cells (including chemotaxis, microbial killing 
mechanisms, and, possibly, ADCC function) appear to be suppressed by interactions 
with HIV. Upregulation of surface molecules such as integrins may be seen, while 
the function and/or expression of other cell surface molecules (i.e. complement 
receptors) may be downregulated. While some of these effects are controversial and 
not widely accepted, others appear to be emerging as real phenomena. It is plain 
that HIV infection can no longer be viewed exclusively as an infection of T cells, 
with the macrophage as an unimportant secondary target. While the primary effect 
of HIV on T cells appears to be cell death (21), the effects on macrophages are 
subtle and varied. The overall result, however, appears to be a downregulation of 
monocyte functions and a resultant suppression of immune defenses against 
pathogens and tumors. The effects of SIV, FIV and BIV have yet to be fully 
described and their effect on monocyte function remains to be determined. With the 
possible exception of SIV, however, these Antiviruses do not appear to affect 
monocytes identically to HIV. 
Some of the effects of Antiviruses on macrophage function remain to be more 
fully characterized and described. Much of the current focus, however, is on 
determining mechanisms for the immune function changes caused by HIV. Retroviral 
proteins, particularly the envelope and transmembrane protein, appear to be good 
candidates to mediate many of the alterations in macrophage function. In addition, 
the p24 core protein has been recently implicated in changes in immune function 
(115,146,147). The effects on macrophage molecules are just beginning to be 
determined, and signal transduction mechanisms have not been described for any of 
these phenomena. This molecular emphasis will, most likely, define the direction of 
future research on lentiviral effects on macrophage function. 
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MONOCYTE FUNCTION IN CATTLE EXPERIMENTALLY INFECTED WITH 
BOVINE IMMUNODEFICIENCY-LIKE VIRUS 
A paper published in Veterinary Immunology and Immunopathology' 
Anna H. Rovid, Susan Carpenter, James A. Roth 
Abstract 
The effects of bovine immunodeficiency-like virus (BIV) on the function of 
monocytes recovered from experimentally infected cattle or upon monocytes 
infected in vitro were examined. Infection with the R29 isolate of BIV appeared to 
have relatively little effect on monocyte function in cattle during the first 2 years 
post-inoculation (PI). For the first 4 to 8 months PI, monocyte phagocytosis of 
opsonized Staphylococcus aureus tended to be lower (P = 0.06) in BIV infected 
calves than in control animals. After 8 months PI, however, phagocytosis became 
equal between the two groups. Random and chemotactic migration and antibody-
dependent cell-mediated cytotoxicity (ADCC) did not appear to be affected by BIV 
infection. Monocytes from BIV infected cattle were able to respond to in vitro 
treatment with interferon 7 similarly to monocytes from control cattle. Although 
experimental infection with BIV R29 resulted in minimal effects on monocyte 
function, this result could have been due either to a low virus burden in vivo or 
because BIV is intrinsically unable to affect monocyte function. To distinguish 
between these possibilities, monocytes from control, uninfected cattle were treated 
with BIV virus in vitro. Treatment of normal monocytes with supernatants from 
BlV-infected fetal bovine lung cells significantly (P < 0.05) increased phagocytosis 
'Reprinted by permission from Vet, Immunol. Immunopathol. 1995, 45, 
31-43. Copyright ® Veterinary Immunology and Immunopathology. 
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and random and chemotactic migration and decreased ADCC, in a dose-dependent 
manner. It appears, therefore, that the normal function of peripheral blood 
monocytes in the BIV R29 infected animals may be due to a low virus burden 
rather than to the inability of BIV to affect monocyte function. The in vitro infection 
results also raise the possibility that the function of monocyte derived cells at local 
sites of BIV replication may be altered. 
Introduction 
Bovine immunodeficiency-like virus (BIV) is a lentivirus of cattle that shares 
genetic, antigenic, and structural similarity with the human immunodeficiency virus 
type 1 (HIV-1) (Gonda et al., 1987). BIV was first isolated in 1969 from an 8-year 
old cow with persistent lymphocytosis, generalized lymph node hyperplasia, and 
progressive weakness and emaciation (Van der Maaten et al., 1972). More recently, 
the AIDS epidemic and interest in animal models for AIDS has renewed interest in 
BIV. Although serologic surveys demonstrate BIV antibodies in 4% to 11% of cattle 
in some areas of the U.S. (Amborski et al., 1989; Black, 1990), relatively little is 
known about the effects of BIV infection on the bovine immune system. It is not yet 
known whether BIV causes significant immunosuppression; however, changes in 
immune function have been reported relatively early after BIV infection (Stott et 
al., 1989; Martin et al., 1991; Flaming et al., 1993). In initial observations, 
inoculation of calves with the original R29 isolate produced a mild nonpersistent 
lymphocytosis and enlargement of subcutaneous lymph nodes (Van der Maaten et 
al., 1972). More recently, we (Carpenter et al., 1992) have confirmed that calves 
inoculated with BIV have early histopathological changes similar to those seen in 
early cases of HIV-1 infection, including follicular hyperplasia in lymph nodes and 
spleen. Other recent reports describe a selective depletion of CD4'^ T cells 3 to 4 
months after inoculation with the R29 isolate (Stott et al., 1989), both decreased 
(Martin et al., 1991) and increased (Flaming et al., 1993) lymphocyte blastogenesis, 
and depressed neutrophil function (Flaming et al., 1993). Recently, Onuma et al. 
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have observed a depression of monocyte functions on a single occasion in three 
animals (Onuma et al., 1992), Long-term studies on the influence of BIV infection 
on monoQ^e function have not, however, been published. 
In this study, we have measured phagocytosis, ADCC, and random and 
chemotactic migration in monocytes isolated from a group of cattle experimentally 
infected with the R29 isolate of BIV. We also determined whether monocytes from 
BIV infected cattle were capable of responding to activating agents such as 
interferon. In addition, we treated normal monocytes in vitro with BIV, to determine 
whether the virus, in sufficient concentration, is able to affect monocyte function. 
Materials and Methods 
Experimental animals 
Experimental infection of the calves with BIV and the virologic aspects of 
infection have been previously described (Carpenter et al., 1992; Flaming et al., 
1993). Briefly, 2-4 month old male Holstein calves were determined to be 
serologically negative for BIV and bovine leukemia virus and randonfily assigned to 
BIV (n = 4) or control groups (n = 5). All but one BIV infected animal were also 
free of antibodies to bovine syncytial virus. Stocks containing the only available 
isolate of BIV were known to contain a noncytopathic strain of bovine virus 
diarrhea virus; therefore, all calves were first immunized 2 and 4 weeks prior to 
BIV inoculation with a commercial killed bovine virus diarrhea (BVD) vaccine. The 
BIV animals each received an intravenous dose of 1.8 x l(y* syncytium forming units 
of the R29 isolate of BIV in fetal bovine lung (FBL) cells. The control animals were 
simultaneously inoculated with a non-cytopathic strain of BVD (field isolate of a 
noncytopathic BVD virus from persistently infected cattle obtained from S. Bolin, 
NADC, Ames, lA) and FBL cells. No immune functions were examined for the first 
3 months of infection to allow the animals time to eliminate the BVD virus and to 
prevent interference of BVD with immune function. Starting 4 months after 
inoculation with BIV, blood monocyte function was assayed every 2 to 4 weeks for 2 
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years. 
Monocyte isolation for junction assays 
Whole blood was collected into acid citrate dextrose anticoagulant and 
mononuclear cells were isolated by centrifugation at 1500 x g, collection of the buffy 
coat, and hypotonic lysis of erythrocytes as previously described (Roth et al., 1981b). 
Monocytes for functional assays were isolated by adherence to tissue culture flasks. 
Flasks were prepared by coating for 15-20 minutes with autologous plasma before 
adding RPMI 1640 (GIBCO Laboratories, Chagrin Falls, OH) supplemented with 
100 U/ml penicillin, 100 /ng/ml streptomycin, and fetal bovine serum (FBS) for a 
final concentration of 10% FBS and 10% autologous plasma in RPMI. An average 
of 3 X 10* mononuclear cells were added to each flask and, after a 1 to 2 hour 
incubation period (ST'C in 5% CO2) to allow the monocytes to adhere, the 
nonadherent cells were removed by washing 5 times with warm (37 °C) RPMI 
without antibiotics or FBS. The adherent monocytes were then detached by 
incubation in warm (SVC) phosphate buffered saline for 45 minutes (Bendixen, 
1981). Monocytes were resuspended for assays at 3.5 x 10® cells/ml in medium M199 
(GIBCO Laboratories, Chagrin Falls, OH) with 100 U/ml penicillin, 100 /xg/ml 
streptomycin and 10% FBS. Monocyte purity (93% ± 4% by nonspecific esterase 
staining) and viability ( 94% ± 5% by trypan blue stain) were generally high. 
Vints recovery 
BIV virus was isolated by co-cultivation of monocytes or unfractionated 
mononuclear cells with fetal bovine lung (FBL) cells, an indicator cell line which 
forms syncytia when infected with bovine retroviruses. Mononuclear cells were 
isolated as described above and 10' cells were added to cultures of FBL cells 
(except at 6 months, when 2 x 10' cells were used). Virus replication was detected 
by syncytium formation in the FBL cells and indirect immunofluorescence as 
previously described (Carpenter et al., 1992), Co-cultures of FBL cells and 
mononuclear cells were followed for 5 passages before they were considered to be 
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negative for virus. 
To detect BIV in monocytes, the adherent monocyte population was isolated 
from mononuclear cells. An excess of mononuclear cells was added to tissue culture 
flasks (0.5 X 10® or 1 x 10* mononuclear cells/ T25 flask). The adherent cells were 
washed repeatedly on day 0 and day 1 before adding FBL cells to each flask of 
monocytes. Monocytes purified in this way generally result in approximately 0.2 to 1 
X 10® monocytes per 25 cm^ tissue culture flask, as well as improved purity over 
monocytes prepared for monocyte function assays. After purification of monocytes, 
equal numbers of FBL cells were added to each flask of monocytes. Co-cultures 
were then monitored daily for syn<ytium formation. Cultures were followed for at 
least one month (3-4 passages) before determining cultures to be negative for virus. 
In all cases, virus identity was serologically confirmed by indirect fluorescent 
antibody staining of infected FBL cells with bovine anti-BIV antibodies as 
previously described (Carpenter et al., 1992). Parallel cultures were stained with 
antibodies to bovine leukemia virus to confirm the absence of co-infection with 
bovine leukemia virus (BLV). 
Monocyte function assays 
Parameters for bovine monocyte function assays were established in initial 
experiments (data not shown) by varying incubation times and reagent 
concentrations. 
Monocyte phagocytosis was measured by the ingestion of heat-killed ('"I) 
iododeoxyuridine-labelled Staphylococcus aureus (Roth et al., 1981a) during a 12-14 
hour incubation (overnight) beginning immediately after monocyte isolation. 
Monocytes were added to 12 x 75 mm polystyrene tubes (Becton-Dickinson 
Labware, Lincoln Park, NJ), at a concentration of 5.25 x 10^ cells in 450 /xl M199 
(supplemented with 100 U/ml penicillin, 100 Mg/ml streptomycin and 10% FBS) per 
sample. Monocytes were allowed to re-adhere for 30 minutes before adding labelled 
S. aureus (at a bacteria to monocyte ratio of 140:1) and bovine anti-S. aureus 
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antibody. Samples were placed in a 37°C humidified 5% CO2 incubator for 12 to 14 
hours. The extracellular bacteria were then lysed with lysostaphin (Sigma Chemical 
Co., St. Louis, MO), and cells were washed free of debris by centrifugation 2 times 
at 1250 X g for 10 minutes in cold (4''C) phosphate buffered saline. Radioactivity 
associated with internalized bacteria was then counted in a gamma counter. All 
samples were tested in duplicate. Results are reported as the percent specific 
ingestion of bacteria for the average of the two replicates per sample. 
Antibody-dependent cell-mediated cytotoxicity, random migration and 
chemotactic migration were measured the day after monocyte isolation. Monocytes 
for ADCC were aliquoted to wells of a 96 well plate (Becton-Dickinson Labware, 
Lincoln Park, NJ) at 3.5 x lO' monocytes per well and allowed to adhere overnight. 
Target cells used were ''Cr labelled chicken red blood cells (cRBC), in a monocyte 
to target cell ratio of 3:1. Antibody-dependent cell-mediated cytotoxicity was 
measured over 6 hours as the percent specific lysis of target cells coated with a 
subagglutinating dose of bovine antibodies to cRBC (Roth et al., 1981a). All 
samples were tested in duplicate. 
Monocytes for migration assays were held overnight in siliconized glass tubes 
in a 37° C humidified 5% CO2 incubator. Monocytes from control and BIV infected 
calves were assayed for random and chemotactic migration at 1.6 x 10^ 
monocytes/chamber in a 48 well blind well chamber (Neuroprobe, Rockville, MD) 
with 5.0 fim pore polycarbonate filters (Nucleopore, Pleasanton, CA). Cell culture 
medium (M199) without fetal bovine serum, or 10% zymosan activated bovine 
serum (serum treated with zymosan to activate complement, Roth et al, 1981a) in 
culture medium were used as attractants for random or chemotactic migration, 
respectively. Filters were stained with Diff-Quik (American Scientific Products, 
Columbia, MD) and the number of monocytes that had migrated through the filter 
was quantified by counting 10 oil immersion fields on a light microscope. Each 
sample was tested in duplicate. Results are reported as the average number of 
monocytes migrated per oil immersion field (lOGOx) over 2 hours. 
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Non-specific esterase staining was performed as previously described for 
bovine macrophages (Osbaldiston et al., 1978; Dhingra et al, 1982). 
Interferon treatment 
On 5 days during months 7 and 8 post-inoculation (PI), monocytes from each 
animal were divided into two aliquots. One was treated overnight (12-14 hours, in a 
37°C humidified 5% CO2 incubator) with 200 U/ml bovine recombinant interferon 
7 (lot AE62, gift of Ciba-Geigy, Basel, Switzerland); the other aliquot served as an 
untreated control. Antibody-dependent cell-mediated cytotoxicity, random migration 
and chemotactic migration were assayed the following day as above. Not all assays 
were done on all animals on all days, as insufficient numbers of monocytes were 
isolated from some animals on some days. 
Monocytes treated in vitro with BIV 
BIV virus isolated from monocytes of animal #346 was grown in FBL cell 
culture and 1.3 x 10" syncytium forming units of virus in FBL cells were inoculated 
intravenously into a 5 month old, BVD and retrovirus negative calf. BIV was 
isolated by co-culturing monocytes from this calf with FBL cells every 2 to 4 weeks 
for 2 years, starting 2 weeks post-inoculation. Virus isolated at 6 months PI at a low 
passage number (PI) was used to produce stocks of cell-free BIV. Virus cultures 
were fed daily with uninfected FBL cells, and cell supernatants were removed daily, 
pooled, and clarified by centrifugation at 850 x g for 30 minutes. Virus supernatants 
contained 800 syncytium forming units/ml. Control supernatants were 
simultaneously collected from uninfected FBL cells. 
Eleven age-matched juvenile Holstein cattle were determined to be negative 
for BIV, BLV and BSV by virus isolation from mononuclear cells, as well as by 
Western blot and agar gel immunodiffusion for antibodies to BIV, or BLV and 
BSV, respectively. Monocytes were isolated from each animal and divided into 4 
aliquots. Each aliquot of monocytes was then treated overnight (12-14 hours in a 
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37°C humidified 5% CO2 incubator) with dilutions of either cell-free virus or 
control supernatants. The multiplicity of infection was 10"^ syncytium forming units 
(SFU) of virus per monocyte for migration and ADCC assays, and 10'^ SFU for 
Staphylococcus aureus ingestion. Monocyte random and chemotactic migration, 
ADCC, and Staphylococcus aureus ingestion were then tested. 
Statistical analysis 
Data comparing BIV to control animals were analyzed using the general 
linear models procedure of SAS (SAS Institute Inc. Cary, NC). A repeated 
measures analysis of variance was used to account for the repeated sampling over 
time. Type I sums of squares were calculated for treatment (BIV or control), animal 
within treatment, date, treatment by date interaction, and animal by date within 
treatment. The animal within treatment term was used as the error term for testing 
treatment effects. 
The effects of treatment with interferon 7 were tested using a split, split plot 
analysis of variance. BIV infection status was the whole plot; interferon treatment 
was used as a subplot, with date treated as a sub-sub plot. Type I sums of squares 
were used for testing, with animal within treatment as the whole plot error term. 
Animal by interferon within treatment group was used as the error term for testing 
interferon effects and the treatment by interferon interaction. Interferon effects 
were evaluated using only data from days where interferon was used. 
The effects of in vitro treatment with BIV were analyzed by linear 
regression, testing for lack of fit, non-zero slope and adequacy of linear model. 
Samples were blocked by animal. 
Results 
Virus isolation and clinical signs 
BIV was consistently recovered from mononuclear cells except on two 
occasions (table 1). At 12 and 18 months PI, BIV could not be recovered from 
Table 1: BIV isolation from infected animals 
Animal 
4 - 8  M o n t h s  P I  9 - 17 Months PI 18 - 24 Months PI 
Monocyte' MNL" Monocyte MNL Monocyte MNL 
340 0/2"= 3/3 0/4 0/1 2/6 1/2 
341 0/2 3/3 0/4 0/1 3/6 1/2 
342 0/2 3/3 0/4 1/1 6/6 2/2 
346 1/3 3/3 
Virus isolation is summarized as the ratio of positive isolations from mononuclear cells or monocytes divided by 
the number of times virus isolation was attempted during the time period. BIV could not be isolated from any of 
the control animals at any time. 
"Monocytes: BIV isolation from monocytes. 
•"MNL; BIV isolation from unfractionated mononuclear cells. 
" Number of times BIV was recovered/number of attempts to isolate virus. 
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mononuclear cells of animals #340 and #341. At these times, BIV was isolated only 
with difficulty from animal #342, requiring more passages in vitro before first 
detection of virus. At 24 months PI, virus was again isolated from mononuclear cells 
of all infected animals. 
Interestingly, although virus could be recovered from unfractionated 
mononuclear cells early in infection, virus was not recovered from purified 
monocytes of most animals until 18 months PI (table 1). After 18 months PI, BIV 
was recovered consistently from mono(ytes from animal #342. In animal #340 and 
#341, virus was isolated from monocytes first sporadically, then later more 
consistently. With increasing time after infection, syncytia were detected at earlier 
passages of the FBL cells during co-culture. BIV was not isolated at any time from 
the control animals. 
Calf #346 died during the course of the experiment. This animal developed 
lymphosarcoma 5 months after BIV inoculation and died at 7 months PI. It is 
uncertain whether the death of this animal was related to the BIV infection. During 
the period before its death, this animal had a persistent monocytosis (manuscript in 
preparation). Virus could be isolated from purified monocytes of this animal much 
earlier than from the healthy BlV-infected animals. Virus isolation from monocytes 
from #346 had been previously unsuccessful at 4 months PI; however, monocyte 
cultures established from this animal during month 7 PI produced infectious BIV. 
Monocyte functions for animal #346 were not significantly different between this 
animal and others in his group. Other data from this animal will be described 
further in a separate paper (4th chapter of dissertation). 
All animals except #346 remained clinically normal throughout the 
observation period. Bovine leukemia virus could not be isolated from any of the 
BIV infected cattle, including animal #346. In addition, all BIV infected cattle 
remained seronegative by agar gel immunodiffusion for bovine leukemia virus 
antibodies. 
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Monocyte function 
Data for monocyte function were analyzed separately for three time periods, 
(table 2). The early period includes months 4 to 8 PI, when virus could not be 
isolated from monocytes but could be isolated from mononuclear cells. During this 
time, the greatest differences in monocyte function were observed between the BIV 
infected and control groups (table 2). The second period includes months 9 to 17 PI, 
when virus isolation was consistently unsuccessful from monocytes and isolated in 
only 1 of 3 animals from mononuclear cells. Monocyte functions during this time 
were very similar between the two groups. The final period includes months 18 to 
20 PI. At this time, BIV could be isolated from both monocytes and mononuclear 
cells. 
Monocyte functions measured were not' significantly different between the 
BIV infected and control animals at the P < 0.05 level during any of the three time 
periods. Phagocytic activity (table 2) tended to be reduced (P = 0.06) in the BIV 
group only in the 4 to 8 month period. Chemotactic migration, random migration 
and ADCC were not significantly different between the two groups during any of 
the three time periods (table 2). 
Interferon treatment effects 
Monocytes from the control and BIV infected cattle were also treated with 
200 U/ml of recombinant bovine interferon gamma during months 7 and 8 PI. 
Interferon 7 almost completely inhibited random migration and significantly (P < 
0.05) decreased chemotactic migration (table 3). Interferon 7 also significantly (P < 
0.05) increased ADCC (table 3). Interferon effects on phagocytosis of S. aureus by 
control monocytes were highly variable; therefore, these results are not presented. 
Treatment with interferon affected monocyte chemotaxis, random migration, and 
ADCC similarly in both groups, when data were evaluated by a split plot analysis of 
variance. 
Table 2; Monocyte function in BIV infected and control cattle 
4 - 8 Months PI 9- 17 Months PI 18- 20 Months PI 
Assay Control BIV Pr > F Control BIV Pr > F Control BIV Pr > F 
n = 5 n = 4* n = 5 n = 3 n = 5 n = 3 
5. aureus 
Ingestion (%) 
29 22 .06 30 29 .23 28 28 .74 
ADCC 
(% specific lysis) 
34 35 .82 30 32 .51 16 21 .24 
Random 
Migration 
(monocytes/hpf) 
10.3 14.3 .30 5.1 3.4 .35 9.6 6.3 .23 
Chemotaxis 
(monocytes/hpf) 
58.6 76.4 .13 29.1 24.2 .26 51.4 42.7 .50 
Pr > F: The probability of having a greater F value by chance for the comparison of BIV to control groups. 
Abbreviations used: hpf = high power field. ADCC = antibody-dependent cell cytotoxicity. PI = post-inoculation, 
n = number of animals in each group 
(' n = 4 for months 4 to 7 PI. n = 3 for month 8 PI). 
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Table 3: The effect of interferon 7 on monocyte function assays in control and BIV 
infected animals 
Controls 
(n = 5) 
BIV 
(n = 4) 
Assay 
No 
interferon 
Interferon 7 
200 U/ml 
No 
interferon 
Interferon 7 
200 U/ml 
ADCC 
(% specific lysis) 
35.9' ± 4.2 50.6" ± 6.0 39.3* ± 4.6 58.2" ± 5.2 
Random Migration 
(monocytes/hpf) 
8.3 ± 3.7 0.2 ± 0.1 15.1 ± 7.1 0.6 ± 0.5 
Chemotaxis 
(monocytes/hpf) 
38.3' ± 10.5 1.8" ± 0.4 63.2' ± 14.1 1.4" ± 0.6 
*Mean ± standard error of the mean. 
Values with different superscripts are significantly different at P < 0.05. 
In vitro treatment of monocytes with BIV 
MonoQ'tes treated in vitro with supernatants from BIV infected FBL cells 
("cell free virus") were significantly different from monocytes treated with uninfected 
FBL cell supernatants in all functions examined. Cell-free virus significantly ( P < 
0.05) increased random and chemotactic migration and S. aureus ingestion, and 
significantly ( P < 0.05) decreased ADCC (figure 1). These effects were all dose-
dependent and repeatable. Monocyte viability was not, however, affected by 
treatment with BIV (data not shown). Monocyte supernatants were also able to 
affect monocyte function after pelleting out virus by centrifugation at 75,000 x g for 
16 hours. The absence of infectious virus in this centrifuged supernatant was 
confirmed by co-cultivation with FBL cells. 
BIV infection of FBL cells does result in the formation of syncytia and 
eventual lysis of some cells. As a control for the effects of FBL cell lysis by BIV, 
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Figure 1: The effects of treatment of monocytes in vitro with dilutions of 
supematants from BlV-infected FBL cells (percent BIV supernatant). Monocyte 
migration, Staphylococcus aureus ingestion, and ADCC function were measured. 
Data points for all assays do not show a significant deviation from a straight line, 
and all lines have a significant non-zero slope (P < 0.01 for ADCC, random and 
chemotactic migration. P < 0.04 for Staphylococcus aureus ingestion.) 
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uninfected FBL cells were lysed by repeated freeze-thawing. Supematants collected 
from these lysed FBL cells were then compared to supematants from unlysed, 
uninfected FBL cells. Both random and chemotactic migration were nearly identical 
between monocytes treated with lysed or unlysed FBL supematants (data not 
shown). The effects of cell-free viras did not, therefore, appear to be simply due to 
FBL cell lysis by virus. 
Discussion 
In cattle experimentally infected with the R29 isolate, we found no significant 
effect of infection on monocyte function during the first 2 years PI. Chemotactic and 
random migration and ADCC were not significantly different between the BIV and 
control groups at any time (table 2). Phagocytosis tended to be reduced (P = 0.06) 
in the BIV group early in infection, but became normal after 8 months PI. In 
addition, treatment with interferon significantly (P < 0.05) decreased migration and 
increased ADCC of monocytes from both groups of cattle, indicating that the cells 
from the R29 infected cattle were capable of responding normally to activating 
cytokines. Nevertheless, when directly treated with vims-containing supematants in 
vitro, all monocyte functions examined were significantly affected. 
Macrophages are important target cells for most lentivimses. Our 
experiments support the findings of Onuma et al. (1992) that BIV, like other 
lentivimses, infects macrophages. In our experiments, BIV could not be recovered 
from monocytes until 18 months post-inoculation. The vims isolated from monocytes 
of animal #346 was inoculated intravenously into another calf. BIV could be 
consistently isolated from monocytes in this animal starting at 2 weeks PI, for at 
least the first year after infection. The vims recovered from monocytes did, 
therefore, appear to retain its ability to productively infect monocytes. These data 
are suggestive of an expansion of cell tropism in the group of R29 vims infected 
cattle. Virus recovery by cell type is not, however, available for the earliest periods 
67 
of infection. We cannot, therefore, conclusively determine whether the R29 virus 
has expanded or shifted its tropism during the course of infection. We also cannot 
exclude the possibility that monocytes were infected either with latent virus or at a 
low level that could not be detected. Technical difficulties are, however, unlikely to 
account for the inability to recover virus during this time, as BIV was recovered 
from monocytes of other BlV-infected animals at the same time (data not shown). 
Infection with the R29 isolate of BIV did not appear to produce dramatic 
impairments in monocyte function during the first 2 years PI. In fact, during the last 
period monocyte function data were analyzed for the R29 BIV infected cattle, 
monocytes were producing infectious BIV in culture. Nevertheless, monocyte 
migration, phagocytosis and ADCC continued to be normal. Monocyte functions 
have also been found to be normal in the calf inoculated with monocyte-derived 
virus from animal #346 (data not shown). One possibility is that virus replication 
might not be high enough in vivo during the first 2 years PI to significantly affect 
monocyte function. Alternatively, BIV might simply be in too low concentration in 
the environment of peripheral blood monocytes to affect function, although virus 
concentrations might be higher in other tissues. In BIV infected cattle, a very low 
percent of blood leukocytes appears to be infected with the virus (Carpenter et al., 
1992). Our experiments treating monocytes in vitro with BIV do support the 
hypothesis that BIV can affect monocyte function, if virus is in sufficient 
concentration. In this experiment, supernatants from BlV-infected FBL cells were 
known to contain 10"^ or 10 ' infectious virions per monocyte; however, these 
supernatants are also expected to contain substantial amounts of inactivated or 
infectious virus. We cannot at this time determine whether the apparent effects of 
BIV in vitro are due to a direct effect of the virus or possibly to a cytokine or other 
factor induced by BIV infection of FBL cells. 
Onuma et al. (1992) found depressed monocyte phagocytosis on a single 
occasion in 3 calves infected with BIV. Phagocytosis was depressed in 2 calves 
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measured at either 15 or 27 weeks PI but not in one calf measured at 45 weeks PI. 
This is consistent with the tendency that we found for depressed monocyte 
phagocytosis at 4-8 months PL Interestingly, this occurred at a time when virus was 
readily recovered from mononuclear cells. MonoQrte phagocytosis did return to 
normal after this time, concurrent with decreasing ease of virus recovery. The 
physiologic significance of the transient decrease in phagocytosis found in both 
experiments is, however, unclear. In addition, further experiments are necessary to 
resolve the discrepancy between the in vivo and in vitro effects of virus on 
phagocytic function. 
Onuma et al. (1992) also found significant decreases in monocyte oxidative 
metabolism and monocyte chemotaxis on one occasion in each infected animal. 
Although we did not measure the oxidative burst, our data generally show no 
significant effect of BIV on monoq'te chemotaxis in infected animals. 
In HIV-1 infection, most monocyte abnormalities appear late in the course of 
disease. Although decreases in monocyte chemotaxis (Smith et al.,1984; Poli et al., 
1985) and ADCC (Bender et al., 1988) have been reported in AIDS patients, these 
abnormalities do not appear to be present in asymptomatic, HIV-1 infected 
individuals (Poli et al,, 1985; Estevez et al., 1989). Therefore, the absence of 
functional impairment of monocytes in clinically normal cattle is consistent with 
studies of monocyte function in HIV-1 infected, asymptomatic individuals. In 
addition, our studies with in vitro treatment of monocytes with BIV support the 
likelihood that monocyte function might be affected in cattle at times when the virus 
burden is high, or possibly in environments where virus is actively replicating, 
possibly lymph node or lung. 
A tendency toward transient suppression of monocyte phagocytosis (P = 
0.06), therefore, appeared to be the only abnormality in monocyte function seen 
during the first 2 years after inoculation of cattle with the R29 virus. Nevertheless, it 
appears that BIV can affect monocyte function when monocytes are inoculated with 
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virus in vitro. The BIV infected cattle are part of a long-term study on immune 
function and BIV; more dramatic impairments in monocyte function may appear 
over the course of time, if virus replication increases late in the course of infection. 
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ENHANCEMENT OF MONOCVTE MIGRATION AND PHAGOCYTOSIS BY THE 
BOVINE IMMUNODEFICIENCY-LIKE VIRUS GAG PROTEINS 
A paper submitted to Cellular Immunology 
Aima H. Rovid, James A, Roth 
ABSTRACT 
Supematants from bovine immunodeficiency-like virus (BIV) infected fetal 
bovine lung cells have been previously shown to affect monocyte random migration, 
chemotaxis, phagocytosis, and antibody-dependent cell-mediated cytotoxicity 
(ADCC) in vitro (1). The experiments in this report demonstrate that the BIV Gag 
(core) proteins can enhance monocyte random migration, chemotaxis and 
phagocytosis. Supematants from BlV-infected cells contained 10-30 kDa and 30-50 
kDa proteins which significantly (P < 0.05) increased monocyte chemotaxis. The 30-
50 kDa protein(s) could be cleaved by limited proteolysis into 10-30 kDa active 
components. Affinity purification with monoclonal anti-p26 (capsid) antibodies 
yielded preparations which were active in the random migration, chemotaxis, and 
phagocytosis assays, but did not affect ADCC. Furthermore, the activity of the 
affinity purified preparation could be specifically neutralized by hyperimmune rabbit 
serum against the BIV Gag proteins. A recombinant Gag protein, consisting 
primarily of BIV p26, also enhanced monocyte random and chemotactic migration. 
It appears, therefore, that direct treatment with affinity purified BIV Gag proteins, 
or with a recombinant Gag protein, is able to significantly affect the function of 
normal monocytes in vitro. The factors affecting monocyte migration and 
phagocytosis appear to be one or more breakdown products of the BIV Gag 
polypeptide precursor, particularly those containing the p26 (capsid) protein. 
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INTRODUCTION 
Bovine inimunodeficieni^-Iike virus (BIV) is a lentivirus of cattle that has 
been postulated to affect immune function. BIV infection, to date, has not been 
associated with clinical immunodeficienQr (1-6); however, experimental infection has 
been associated with follicular hyperplasia in lymph nodes and spleen (7,8) and 
subtle changes in numbers and function of neutrophils and T cells (2,3,5). Although 
the complete cell tropism of BIV has not been reported, there is evidence that 
monocytes are one of the target cells for BIV (4 and unpublished data). 
The related (9) lentiviruses HIV and FIV cause alterations in monocyte 
function (10-15); such changes may be present in BIV infection, as well. Onuma et 
al (4) reported decreases in monocyte phagocytosis, migration, and 
chemiluminescence in a single sample of 3 BIV infected calves. We were able to 
confirm only a tendency (P = 0.06) for decreased phagocytic function in 
experimentally infected calves followed for 2.5 years post-inoculation (1). In vitro 
experiments, however, raised the possibility that changes in monocyte function were 
not seen in these animals because titers of circulating virus were not sufficiently 
high to affect monocyte function. In vitro treatment of normal bovine monoq^tes 
with crude BlV-containing cell supernatants did result in significant (P < 0.05) 
dose-dependent increases in monocyte random migration, chemotaxis and 
phagocytosis, and decreases in antibody-dependent cell-mediated cytotoxicity (1). 
Further experiments were necessary to determine whether the factor(s) 
affecting monocyte function in these crude preparations were viral components or 
virus-induced cellular molecules. We have previously reported that infection of 
monocytes was not required for changes in cell function (1). This report further 
characterizes the active factor in the BlV-containing cell supernatants, and the 
evidence that this factor is one of the BIV Gag (core) proteins. 
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MATERIALS AND METHODS 
Experimental Animals 
Eleven age-matched young adult (1-2 year old) male Holstein cattle were 
tested and found to be negative for BIV, bovine leukemia virus (BLV) and bovine 
syncytial virus (BSV) by virus isolation from mononuclear cells, and by Western blot 
or agar gel immunodiffusion for antibodies to BIV, BLV and BSV (1,5,7). 
Monocytes from these animals were isolated in single cell suspension by adherence 
to tissue culture flasks and recovery with phosphate buffered saline (PBS, pH 7.2), 
as previously described (1). Monocytes isolated from each animal were divided into 
several aliquots. Each aliquot was treated overnight (12-14 hours) with various BIV 
or control preparations diluted in tissue culture medium. Tissue culture medium 
used for all experiments was medium M199 (GIBCO Laboratories, Chagrin Falls, 
OH) with 10% fetal bovine serum, 100 U/ml penicillin, and 100 /ig/ml 
streptomycin. Monocyte random migration, chemotactic migration, antibody-
dependent cell-mediated cytotoxicity (ADCC) or Staphylococcus aureus ingestion 
were then tested. 
Monocyte Function Assays 
Random and chemotactic migration, antibody-dependent cell-mediated 
cytotoxicity (ADCC), and Staphylococcus aureus ingestion were performed as 
previously described (1), with minor modifications in cell numbers or incubation 
times. 
Briefly, random and chemotactic migration were performed in blind well 
chambers, with 5.0 x 10^ monocytes/chamber. Cell culture medium or 10% zymosan 
activated serum (bovine serum treated with zymosan to activate complement) in 
culture medium were used as attractants for random or chemotactic migration, 
respectively. Filters were stained with Diff-Quik (American Scientific Products, 
Columbia, MD) and the number of monocytes that had migrated through the filter 
was quantified by counting 2 oil immersion fields on a light microscope. Each 
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sample was tested in duplicate. Results are reported as the average number of 
monocytes migrated per oil immersion field (lOOOx) during 90 minutes. 
Monocyte phagocytosis was measured as the percent specific ingestion of 
heat-killed ('"I) iododeoj^ridine-labelled Staphylococcus aureus (16) during a 6 
hour incubation at 37°C (1). Each sample contained 7.0 x 10^ monocytes in 550 jwl 
M199, S. aureus (at a bacteria to monocyte ratio of 100:1) and bovine anti-5. aureus 
antibodies. After incubation, extracellular bacteria were lysed with lysostaphin 
(Sigma Chemical Co., St. Louis, MO), and cells were washed free of debris by 
centrifugation in cold phosphate buffered saline. Results are reported as the percent 
specific ingestion of bacteria for the average of the two replicates per sample. 
Antibody-dependent cell-mediated cytotoxicity was measured over 6 hours as 
the percent specific lysis of ^'Cr-labelled chicken red blood cells (cRBC) coated with 
a subagglutinating dose of bovine antibodies to cRBC (1,16). All samples were 
tested in duplicate. 
Virus Source 
The BIV virus used in all experiments was obtained from monocytes of a 
healthy, persistently infected animal (#808), 2.5 years after inoculation with the R29 
isolate of BIV (1,17). Fetal bovine lung (FBL) cells were infected by co-cultivation 
with monocytes isolated from the infected animal, as previously described (1). These 
FBL/virus cultures were then used to produce stocks of cell-free BIV. Virus cultures 
were fed daily with uninfected FBL cells, and cell supernatants were removed daily, 
pooled, and clarified by centrifugation at 850 x g for 30 minutes. Virus supernatants 
contained 1-6 x lO' syncytium forming units/ml of BIV. Control supernatants were 
simultaneously collected from uninfected FBL cells. 
Virus identity was confirmed by indirect fluorescent antibody staining of 
infected FBL cells with bovine anti-BIV antibodies as previously described (7). 
Parallel cultures were stained with antibodies to bovine leukemia virus, bovine 
syncytial virus and bovine virus diarrhea virus to confirm the absence of co-infection 
with these viruses. 
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Recombinant Gag 
Recombinant Gag3 and control (trpE) protein preparations were a gift of Dr. 
Jeffrey Isaacson. The 65 kDa Gag3 protein (corresponding to nucleotides 631-1442 
of the R29 isolate of BIV) consists of the p26 capsid protein and small flanking 
regions, expressed as a trpE fusion protein (18,20,21). The Gag3 protein preparation 
is partially purified from Escherichia coli cells by salt precipitation (21). The trpE 
control is a similar protein preparation from E. coli cells (transfected with the 
pATH vector) which express the 37 kDa trpE protein (21). 
Anti-Gag Antibodies 
The production of a monoclonal antibody (#104) specific for the BIV p26 
(capsid) protein has been previously described (18). To isolate large quantities of 
antibody, hybridoma cells were grown in cell culture in roller bottles (19), and 
proteins in the culture medium were concentrated 32x with a 10 kDa filter (Amicon 
Inc., Beverly, MA). Concentrated monoclonal antibodies were bound to protein G-
coated agarose beads (Sigma Chemical Co., St. Louis, MO) by incubation for 2 
hours at 37°C with rocking, then washed 6 times with PBS (pH 7.2), to remove non­
adherent proteins. The protein G beads contained recombinant protein G which 
does not bind albumin, cell membranes, or Fab fragments (Sigma #P7700). 
Rabbits were also immunized with the recombinant Gag fusion protein 
(Gag3), as previously described (20). High titered serum (reactive to Gag at 1:500 
on Western blot) was heat inactivated at 56°C for 30 minutes to inactivate 
complement. Control sera were obtained from rabbits immunized with the control 
(trpE) antigen preparation and heat inactivated. For some studies, rabbit antibody 
was bound to protein G beads, similarly to monoclonal antibodies. 
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Purification of Supematants 
BlV-containing and control supematants were size fractionated using 
Centriprep filter concentrators (Amicon Inc., Beverly, MA). These concentrators 
retain molecules of approximately 10 kDa, 30 kDa, 50 kDa and 100 kDa. The 10-30 
kDa and 30-50 kDa fractions were further purified with monoclonal anti-p26 
antibodies or polyclonal anti-Gag serum. Fractionated supematants were incubated 
with antibody-coated protein G beads for 2 hours at 37 °C, then overnight at 4°C. 
The beads were washed 6 times with PBS (pH 7.2), then incubated in PBS (pH 2) 
to separate antigens from antibodies. After 1 hour at room temperature, antibodies 
and large proteins were separated from the solution with Centriprep filter 
concentrators and the pH was readjusted to 7. Proteins greater than 50 kDa in 
molecular mass were discarded; proteins of approximately 10-30 kDa or 30-50 kDa 
were retained. The exact protein concentration of all preparations was not tested; 
however, it was estimated that most antibody purified proteins were used at 
approximately 0.1 fig/ ml (approximately 0.05 fxg per 10® monocytes). 
Neutralization by Rabbit Serum 
In neutralization studies, monoclonal antibody purified 30-50 Kda BIV or 
control supematants (each purified from equal volumes of supernatant, 
approximately 4-6 ml) were incubated with anti-Gag or control rabbit semm for 45 
minutes at 37°C. PBS (pH 7.2) washed protein G-agarose beads were then added 
(19 mg per treatment) and the preparations were incubated for an additional hour 
at 37 °C. The beads, with associated antibodies and bound antigen, were removed 
from the supematants by centrifugation at 400 x ^ for 5 minutes. The supematants 
were filter sterilized with a 0.2 fim syringe filter (Gelman Sciences, Ann Arbor, MI) 
and diluted with tissue culture medium to 4 ml. 
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Heat Treatment 
BIV or control supernatants were incubated at 4°C, 20°C, 37''C, 60°C or 
100°C for 30 minutes. To prevent denaturation of essential proteins in the tissue 
culture medium, concentrated BIV or control preparations were first incubated at 
each temperature, then diluted with fresh tissue culture medium. 
Protease and RNase Treatment 
The 30-50 kDa fractions from BlV-containing or control supernatants were 
incubated for varying lengths of time at 37°C with protease coated agarose beads 
(Sigma Chemical Co., St. Louis, MO). Protease coated bead preparations consisted 
of 6 units of trypsin, 6 units of chymotrypsin, and 2-6 units of a nonspecific bacterial 
protease (Streptomyces griseus) for most experiments. Some preparations were 
treated with 15 units of bacterial protease to confirm the results obtained with a 
combination of proteases, BIV or control supernatants were treated in parallel with 
RNase coated agarose beads (Sigma Chemical Co., St. Louis, MO), as a control for 
exposure to agarose. After incubation, the beads were removed from the 
preparations by centrifugation at 400 x ^ for 5 minutes. The supernatants were then 
filter sterilized with a 0.2 /zm syringe filter, and diluted with tissue culture medium. 
Coomassie blue staining of denaturing SDS-PAGE gels demonstrated a number of 
additional smaller molecular mass bands in the protease treated but not RNase 
treated preparations. 
Statistical Analysis 
Data comparing BIV to control animals were analyzed using the general 
linear models procedure of SAS (SAS Institute Inc. Cary, NC). Data were blocked 
by animal, and Type I sums of squares were calculated for treatment (BIV or 
control), block and error. Heat treatment data were analyzed by linear regression, 
testing for lack of fit, non-zero slope and adequacy of a linear model. Samples were 
blocked by animal. 
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RESULTS 
Physical Characterization • Size, Heat Resistance, and Protease Susceptibility. 
For the initial characterization of the active factor(s), bioactivity was 
measured as the ability to significantly (P < 0.05) enhance monocyte chemotaxis. 
BIV and control supematants were fractionated into approximate size ranges of 10-
30 kDa, 30-50 kDa, 50-100 kDa, and greater than 100 kDa. Both the 10-30 kDa and 
30-50 kDa fractions of the BIV supematants significantly ( P<0.05) increased 
monocyte chemotaxis (Table 1). Fractions greater than 50 kDa did not increase 
chemotaxis. The 30-50 kDa chemotaxis enhancing factor was determined to be a 
protein: complete protease digestion (6 hours at 37°C) destroyed the activity (data 
not shown). The activity was heat stable to 60" C for 30 minutes, but destroyed by 
boiling (means; 63-65 cells/hpf for control supernatant at 37°C or 100°C and BIV 
supernatant at 100°C; 80-92 cells/hpf for BIV supernatant at 4°C, 20°C, 37°C, and 
Table 1: Chemotaxis of monocytes after treatment with size-fractionated control and 
BIV supematants. 
Mean (monocytes/hpf) 
Size Control BIV SEM Pr > F 
10-30 kDa 56 65 1.6 0.005 
30-50 kDa 23 32 1.8 0.02 
50-100 kDa 44 44 6.2 0.98 
Greater than 100 kDa 64 55 5.3 0.28 
Monocytes were treated with size fractionated BIV and control supematants, and 
the effect on chemotaxis was measured. Migration data from different cell fractions 
cannot be directly compared, as not all fractions were measured on the same date 
and this assay has high variability between different dates (n = 7-9 animals). 
Values are representative of multiple experiments. Abbreviations used: hpf = high 
power field (lOOOX). SEM = standard error of the mean. Pr > F = the probability 
of having a greater F value by chance for the comparison of each BIV treatment to 
its control. 
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60°C; means for all BIV supernatants at temperatures except 100°C are significantly 
different from the control values at P < 0.05 and fit a straight line with a slope of 
zero). 
Limited proteolysis (37 °C for 30 minutes), did not destroy activity; however, 
it altered the size of the active component. BIV and control 30-50 kDa preparations 
were treated with either protease or RNase beads, then separated into 10-30 kDa 
and 30-50 kDa fractions. Before size separation, both RNase and protease treated 
supernatants retained activity (Table 2). The enhancement of chemotaxis, with 
either preparation, was similar to increases mediated by non-enzyme treated BIV 
Table 2; Limited proteolysis, but not treatment with RNase, reduces the size of the 
active factor in BIV supernatants. 
Whole 30-50 kDa 
supernatants 
Supernatants 
after separation by size 
10-30 kDa 30-50 kDa 
Mean ± SEM Mean ± SEM Mean ± SEM 
RNase treated supernatants 
Control (cells/hpf) 43 ± 2.0 38 ± 1.8 48 ± 2.1 
BIV (cells/hpO 52 ± 2.0' 34 ± 1.8 59 ± 2.1' 
Protease treated supernatants 
Control (cells/hpf) 49 ± 2.7 34 ± 4.2 51 ± 1.5 
BIV (cells/hpO 59 ± 2.7" 50 ± 4.2" 52 ± 1.5 
30-50 kDa BIV and control supernatants were treated with protease or RNase for 
30 minutes at 37 °C; after removal of enzyme-coated beads, some preparations were 
separated into 10-30 kDa and 30-50 kDa fractions. Monocyte chemotaxis was tested 
on both the RNase or protease treated, whole supernatants and on these 
supernatants after separation into 10-30 kDa and 30-50 kDa fractions. Values with 
asterisks (*) are significantly different from their control at P < 0.05 (n = 5-9 
animals). Values cannot be compared across columns, as some preparations were 
tested on different dates. Abbreviations used: hpf = high power field (lOOOX). SEM 
= standard error of the mean. 
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supematants. After size fractionation, however, the active component was found to 
be 10-30 kDa, and not 30-50 kDa, in the protease treated BIV preparation. The 
activity was retained in the 30-50 kDa fraction in the RNase treated preparation. 
Immunologic Characterization 
Preliminary data indicated that the factor affecting chemotaxis could be 
neutralized by serum from a steer immunized with killed BIV virus, sera from some 
naturally infected animals, or polyclonal rabbit serum against the BIV Gag (core) 
proteins (data not shown). It, therefore, appeared to be a viral and not a cellular 
component. In particular, it appeared to be one of the BIV Gag proteins. The BIV 
Gag proteins are synthesized as a 53 kDa polypeptide precursor (22). One potential 
candidate, found in FBL cell supematants, is the p26 (capsid) protein. Other 
putative cleavage products of the 53 kDa Gag precursor protein include numerous 
10-49 kDa proteins (22); all of the Gag proteins except p53 fall into the size range 
containing the component active on chemotaxis. 
To determine whether the active factor might, in fact, be one of the Gag 
proteins, antigens were isolated from 30-50 kDa BIV and control supematants by 
binding to anti-Gag antibodies on protein G beads. Semm was obtained from 
rabbits immunized with a recombinant Gag-trpE fusion protein (mainly containing 
the p26 protein) and from control rabbits immunized with the control (trpE) 
preparation. Protein G beads were coated with either control (anti-trpE) or anti-
Gag antibodies; 30-50 kDa BIV and control supematants were then incubated with 
the antibody coated beads. Bound antigens were isolated from the beads by a pH 
change and separated from whole antibodies by size fractionation. Both rabbit 
polyclonal preparations (anti-trpE and anti-Gag) were incubated with control and 
BIV supematants. Only antigens isolated from the BIV preparations with anti-Gag 
serum were able to enhance monocyte chemotaxis (mean ± SEM; 26-30 ± 1.9 
cells/hpf, for control antigens isolated with control or anti-Gag antibodies; 57 + 3.7 
cells/hpf, for BIV antigens isolated with anti-Gag antibodies; Pr > F = 0.005). 
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Antigens from control supernatants, or from BIV preparations incubated with anti-
trpE serum, did not increase monocyte chemotaxis. Similarly, affinity purification of 
either 10-30 kDa or 30-50 kDa BIV fractions with anti-p26 monoclonal antibody 
coated beads resulted in preparations which also significantly (P<0.05) increased 
monocyte chemotaxis (data not shown). 
The effect of these antigens could be neutralized with Gag-specific serum. 
Antigens were first affinity purified from the 30-50 kDa BIV fractions with 
monoclonal anti-p26 antibody coated beads. These antigens were then neutralized 
by treatment with rabbit anti-Gag serum. In initial studies, heat inactivated serum 
from the rabbits immunized with Gag, but not the control rabbits, was able to 
neutralize the effect of the affinity purified antigens on monocyte chemotaxis (data 
not shown). To control for the possibility of immune complexes acting upon the 
monocyte to suppress migration, this technique was then modified slightly: affinity 
purified antigens were incubated with rabbit serum, then allowed to react with 
protein G coated agarose beads. After the beads, associated immunoglobulins, and 
any bound antigen were removed, the remaining preparations were tested on 
monocyte chemotaxis. Affinity purified antigens were neutralized by treatment with 
rabbit anti-Gag serum (mean + SEM: 60 ± 2.3 cells/hpf for controls; 59 ± 2.3 
cells/hpf for BIV antigens; Pr > F = 0.83). BIV antigens were not, however, 
affected by treatment with control serum (mean ± SEM: 60 ± 1.4 cells/hpf for 
controls; 69 ± 1.4 cells/hpf for BIV antigens; Pr > F = 0.001). 
Finally, monocytes were treated with a recombinant Gag fusion protein. This 
protein contains the BIV p26 protein and small flanking regions on both ends of this 
protein, expressed as a trpE fusion protein. Control preparations were treated in 
parallel with the trpE protein. Treatment of monocytes with a minimum of 
0.5 uglvdi. recombinant Gag resulted in a significant (P < 0.05) increase in 
monocyte chemotaxis, as well as random migration (Table 3). Viability of cells 
treated with the recombinant Gag fusion protein or the control (trpE) preparation 
were not significantly different from each other. 
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Table 3: The effect of 1 recombinant Gag on random migration and 
chemotaxis. 
Control Recombinant Gag 
Mean* ± SEM Mean ± SEM Pr>F 
Chemotaxis 33 ± 1.6 44 ± 1.6 0.002 
Random migration 14 ± 1.4 20 ± 1.4 0.03 
Monocyte migration assays were tested after treatment with 0.1 /xg/ml Gag3 
(approximately 0.5 ng Gag3 per 10® monocytes). Mean* = monocytes/ high power 
field (n = 10 animals). Abbreviations used: SEM = standard error of the mean. Pr 
> F = The probability of having a greater F value by chance for the comparison of 
BIV to control groups. 
Other Assess 
Monocyte random migration, Staphylococcus aureus ingestion, and ADCC 
assays were also tested. Monocytes were treated overnight (12-14 hours) with 
affinity purified antigens isolated with the monoclonal anti-p26 antibody (Table 4). 
Random migration and Staphylococcus aureus ingestion were significantly (P < 0.05) 
enhanced by treatment with the affinity purified antigens. ADCC activity was not, 
however, affected, by either the affinity purified antigens (Table 4) or by 
recombinant Gag protein at 1 /ig/ml (data not shown). 
DISCUSSION 
From these experiments, it appears that proteolytic cleavage products of the 
BIV Gag precursor are able to affect monocyte function in vitro. The Gag proteins 
appear to be at least one of the active factors, previously identified in BlV-infected 
cell supematants, which enhance monocyte migration and phagocytosis (1). Antigens 
isolated by binding to either a monoclonal antibody specific for p26, or to rabbit 
polyclonal anti-Gag serum, significantly (P < 0.05) enhanced monocyte chemotaxis, 
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Table 4: The effect of core proteins isolated with monoclonal anti-p26 antibody on 
monocyte ADCC, Staphylococcus aureus ingestion, and random migration. 
Control BIV 
Assay Mean ± SEM Mean ± SEM Pr>F 
Random migration 
(monocytes/hpf) 
24 ± 0.9 31 ± 0.9 0.001 
Staphylococcus aureus ingestion 
(percent ingestion) 
41% ± 1.1 44% ± 1.1 0.02 
ADCC (percent target cell lysis) 17% ± 1.0 19% ± 1.0 0.21 
Monocytes were treated with approximately 0.1 /ig/ml monoclonal antibody purified 
Gag (approximately 0.05 /ig per 10* monocytes for random migration and ADCC, 
and 0.005 /*g per 10* monocytes for S. aureus ingestion. Abbreviations used; ADCC 
= antibody-dependent cell-mediated cytotoxicity, hpf = high power field (lOOOX), 
SEM = standard error of the mean. Pr > F = the probability of having a greater F 
value by chance for the comparison of BIV to control groups (n = 10 animals). 
random migration and Staphylococcus aureus ingestion. The antigens isolated from 
the monoclonal antibody preparations could be specifically neutralized by rabbit 
anti-Gag serum. Finally, a recombinant Gag fusion protein, containing the p26 
protein, enhanced monocyte chemotaxis and random migration similarly to the 
molecule(s) isolated from infected cell supematants. From the latter data, it appears 
that the active component is contained either within or near the p26 protein. A 
second, as yet uncharacterized, factor also appears to be present within the BIV 
supematants, as monocyte ADCC was suppressed by supematants from BIV 
infected cells (1), but was not affected by the BIV Gag proteins. 
The 53 kDa Gag precursor is cleaved into p26 capsid, pl4 nucleocapsid, and 
pl7 matrix proteins (9,22,23). Proteolytic processing of these components is poorly 
understood; it appears, however, that multiple breakdown products, including 
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products of sizes ranging from 10 kDa to 49 kDa are produced (22). In our 
e}qperiments, whole virus (in the > 100 kDa fraction) did not appear to affect 
monoiyte function. This is not surprising, as the Gag proteins are contained within 
the virion and would not be expected to contact monocytes. The Gag proteins can, 
however, be detected in FBL cells (data not shown), and Gag proteins may be 
released into tissues or cell cultures during cell lysis. They may also be present after 
degradation of virus particles. The active factor in the 10-3Q kDa fraction is most 
likely to be the p26 protein; however, this fraction could also contain a number of 
other proteolytic cleavage products of Gag, some of which contain portions of p26. 
The 30-50 kDa fraction may contain active p32, p37, p39, p42 and/or p49 proteins, 
which are known or predicted breakdown products of p53 (22). It is likely that, 
during limited proteolysis, some of these proteins are broken down into smaller 
fragments similar to those found in the 10-30 kDa cell supernatant fraction. It is 
also possible that the 10-30 kDa and 30-50 kDa fractions contain some of the same 
(approximately 30 IcD) proteins, as size fractionation by Centriprep concentrators is 
not exact. 
While it may at first appear surprising that the Gag protein is able to affect 
monocyte function, it is not unprecedented. Recently, the related (9) HIV-1 capsid 
protein has been shown to affect monocyte function and lymphocyte blastogenesis 
(24-26). Treatment with HIV p24 appears to inhibit the induction of lymphocyte 
responses to antigens (24,25) and alter the monocyte response to interferon gamma 
(26). The blastogenesis inhibiting activity has been traced to a fragment of the EflV 
p24 protein containing the conserved 7 amino acid sequence RGSDIAG (25). BIV-
R29 does not contain this particular amino acid sequence within its p26 protein 
(27); however, a relatively conserved amino acid sequence, KTDEIIG, is present at 
a similar position in the BIV p26 protein (amino acids 239-246 of BIV) (27). It is 
not yet known whether this or other BIV peptides are able to affect monocyte 
function. 
The mechanism for the effect of the BIV Gag proteins on migration and 
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phagocytosis is not known. It is likely to be a receptor mediated event, as low 
concentrations of Gag are able to affect monocyte function, and the lentiviral Gag 
proteins are not hydrophobic. One possibility is that Gag mimics a normal cell 
ligand. Potential mechanisms for the enhancement of migration and phagocytosis 
include cytokine induction from monocytes by Gag, or a direct alteration in signal 
transduction leading to a change in the monocyte intracellular enviroiunent. 
In previous experiments, it had been found that monocyte function in 
infected animals was relatively normal (1); however, this may have been a result of 
low levels of virus proteins in the blood. The few reported abnormalities seemed to 
occur during the early stages of infection (1,4), when virus production appeared to 
be at its highest levels (1). These in vivo abnormalities may, however, be a result of 
virus induced alterations in cytokine levels, or other in vivo interactions; the 
alterations in monocyte function reported in vivo (a suppression in migration and 
phagocytosis (4) or tendency for decreased phagocytosis (1)) are opposite to those 
found when monocytes are treated directly with BIV in vitro. 
Although circulating monocytes from infected animals do not appear to be 
greatly affected (1), and virus levels in the blood appear to be low (7), Gag protein 
production at local sites may be high enough to affect the function of tissue 
macrophages. In vitro treatment with recombinant Gag at concentrations of at least 
0.5 Mg/ml results in monocyte functional alterations; such levels might be reached in 
areas of high virus production. The BIV p26 protein has, in fact, been found in 
lymph node follicles by immunohistochemical staining (28). In localized areas, 
therefore, BIV proteins may result in alterations in monocyte function. Although 
there are no published reports of clinical immunodeficiency proven to be caused by 
BIV infection, it is possible that alterations in macrophage function are present 
within the tissues but result in only subtle changes in immunity. It is also not certain 
that the relatively minor changes in monocyte function caused by Gag would cause 
significant clinical abnormalities. They may, however, enhance immunodeficiency 
caused by stress or other microorganisms. At present, it is not clear whether BIV 
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causes immunodenciency, as is suggested by the previous reports of BIV suppression 
of ADCC in vitro (1) and several monocyte functions in vivo (1,4); or whether BIV 
enhances monocyte function, as suggested by the results reported in this paper. It 
appears that BIV has (or induces from infected cells) at least two components that 
affect monocyte function. One appears to enhance functions such as phagocytosis 
and migration; the other appears to suppress ADCC. 
Finally, the finding that BIV Gag is able to affect monocyte functions, 
coupled with the presence of BIV p26 protein in lymph nodes (28) and the 
inhibition of lymphocyte blastogenesis by HIV p24, raises the possibility that BIV 
p26 might affect antigen presentation by macrophages. In both BIV and HIV-1 
infections, reactivity to the Gag protein is lost during the course of infection (20). In 
contrast to HIV, BIV virus production is not likely to be high enough to induce the 
formation of immune complexes; therefore, other mechanisms are more likely to 
result in the loss of anti-Gag antibodies (20). One intriguing hypothesis is that the 
BIV p26 protein, like HIV p24, might inhibit the induction of antigen specific 
responses, including the response to p26 itself. As BIV p26 is able to affect other 
monocyte functions, it is interesting to speculate that this could take place by 
inhibiting the antigen presentation ability of macrophages in the lymph nodes. 
Until recently, it appeared that the lentiviral core proteins merely served a 
structural function. Now, however, it seems that BIV p26, like HIV p24 (24-26), may 
be involved in viral modulation of immune function. In addition to its effects on 
monocyte migration, ADCC, and phagocytosis, there is the potential for its 
involvement in antigen presentation defects and the loss of reactivity to p26 in 
infected animals. These latter effects are speculative, yet they provide intriguing 
ground for further research. The Gag proteins are one of the major proteins in 
infected cells and lentiviral virions (23,29-31); it is likely that they play a greater 
role in lentivirus infection than previously suspected. 
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AN ATYPICAL T CELL LYMPHOSARCOMA IN A CALF WITH 
BOVINE IMMUNODEFICIENCY-LIKE VIRUS INFECTION 
A paper submitted to Veterinary Pathology 
A.H. Rovid, S. Carpenter, L.D. Miller, K.P. Flaming, MJ. Long, 
MJ. Van der Maaten, J.A. Roth 
Abstract 
This paper describes a case of T cell lymphosarcoma in an 11 month old 
Holstein calf experimentally infected with bovine immunodeficiency-like virus (BIV). 
Lymphosarcoma developed at 5 months post-inoculation, concurrent with 
progressive monocytosis. Tumors were found in the thymus, multiple lymph nodes, 
and brain. Tumor cells were CD2^ CD4' CDS' T cells. Infectious BIV could be 
recovered from splenic tissue and blood mononuclear cells. Bovine leukemia virus 
was not present. Because this calf was part of an ongoing experiment on the 
pathogenesis of BIV infection, immune function data were also available both 
before and after lymphosarcoma developed. Neutrophil and monocyte function were 
normal, but lymphocyte blastogenesis was enhanced before the development of 
lymphosarcoma. Follicular hyperplasia in lymphoid tissues was also seen. This case 
raises the possibility that BIV infection may cause or be associated with some cases 
of atypical T cell lymphosarcoma, without evidence of immune suppression at the 
time of tumor onset. 
Brief Communication 
Bovine immunodeficiency-like virus (BIV) is a lentivirus of cattle that shares 
some characteristics with the immunodeficiency-causing lentiviruses; human 
immunodeficiency virus-1 (HIV-1), feline immunodeficiency virus (FIV) and simian 
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immunodeficiency virus (SIV)' Lentivirus-associated lymphomas have been 
recognized in humans, non-human primates, and cats.* '* In cattle, there is a clear 
association of bovine leukemia virus (BLV), an oncogenic retrovirus, with 
multicentric lymphosarcoma in adult cattle; however, no tumors have been 
described in conjunction with the lentivirus BIV. An increased incidence of 
lymphosarcoma has been observed in some herds with BIV; however, these herds 
were also reported to be infected with BLV.'" '^ In this report, we describe a case of 
multicentric T cell lymphosarcoma in an 11 month old calf experimentally infected 
with BIV, but known to be negative for bovine leukemia virus. 
A male Holstein calf (animal #346), 6 months of age, was inoculated 
intravenously with 1.8 X l(y* syncytium forming units of the R29 isolate of BIV, 
This animal was part of a long term study on the pathogenesis of BIV in 
experimentally infected cattle. The details of experimental inoculation, control 
animals, and methods for clinical evaluation have been previously described,^ '' 
Briefly, this animal was evaluated twice each month, starting at 4 months 
postinoculation (PI), for total and differential white blood cell counts, neutrophil 
function, monocyte function, mononuclear cell subset analysis (CD4, CDS, CD6, 
CD2, and markers for B cells, monocytes, and y8 T cells) and lymphocyte 
blastogenesis to mitogens. These assays have been previously described.^ '' ® 
Lymphocyte blastogenesis data was available only to day 115 PI. The presence of 
infectious BIV in cells and tissue samples was detected by co-cultivation with fetal 
bovine lung (FBL) cells. ^ ^ Virus isolation from peripheral blood mononuclear cells 
(PBMC) was attempted at 2, 6, 8, 16, 18, 27 and 29 weeks PI, and virus isolation 
from monocytes was attempted three times, at 17, 18 and 29 weeks PI. 
At 23 weeks (160 days) following inoculation with BIV, systemic enlargement 
of lymph nodes was observed in animal #346. A diagnosis of lymphosarcoma was 
made by lymph node biopsy. Prior to the detection of the tumors, an absolute 
monocytosis was detected by flow cytometry, and confirmed by non-specific esterase 
staining. Monocyte numbers progressively increased from day 112 to day 190, at 
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which date 55% of mononuclear cells were monoqrtes. The calfs condition 
deteriorated over the next month, and the calf died at 29 weeks PI (day 203). 
Interestingly, BIV was detected in purified monocytes isolated from whole blood 
collected on the day of death, but not on the 2 previous attempts. BIV had been, 
however, consistently isolated from peripheral blood mononuclear cells (PBMC) at 
each attempt following infection. PBMC were negative for BLV and bovine syncytial 
virus (BSV) at all times prior to and following experimental infection with BIV. 
A necropsy was done immediately after death and tissues were collected for 
histopathologic, immunologic and virologic studies. For light microscopy, tissue 
samples were fixed by immersion in 10% neutral buffered formalin, embedded in 
paraffin, sectioned at 5 /xm, and stained with Harris' hematoxylin and eosin. 
At post mortem examination, a gray-white subcutaneous mass approximately 
15 X 15 X 20 cm was present in the caudoventral cervical region. The mass extended 
through the thoracic inlet into the thoracic cavity for a distance of 4 cm. Upon 
incision, bands of white fibrous coimective tissue divided the mass into irregular 
lobules. Multiple foci of caseous necrosis, or necrosis with hemorrhage, up to 3 cm 
in diameter were randomly distributed within the tumor. Dorsally the mass was 
concave and caused compression of the trachea and esophagus. Carotid arteries in 
the caudal cervical region were embedded within the mass, and jugular veins were 
compressed laterally. This mass was presumed to be a thymic tumor. 
The thorax contained approximately 5 liters of clear amber fluid and a few 
fine strands of fibrin. Paired lymph nodes, including parotid, mandibular, 
retrophaiyngeal, superficial cervical, and superficial inguinal nodes, were 
symmetrically enlarged to 5 - 10 times normal size. Thoracic and abdominal nodes 
ranged from normal size and appearance to 20 times normal size for some 
mesenteric nodes. Variable enlargement and pallor of hemal nodes was also found 
in the subcutis, thorax and abdomen. A cluster of enlarged hemal nodes occurred in 
the subiliac region. Plaques of gray-white tissue were found in the frontal sinuses 
and on the ventrorostral dura mater extending caudally to the hypothalamic area. 
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Small areas of atelectasis were present in anteroventral lung lobes. liver, spleen, 
and bone marrow were unremarkable. 
Microscopically, the thymic mass was composed of sheets of lymphoid cells 
with slight to moderate amounts of lightly eosinophilic q^oplasm (Fig. 1). 
Cytoplasmic borders were usually indistinct in compact areas, and the cells were 
round to oval with distinct q^oplasmic borders at the periphery where invasion of 
adipose tissue occurred. The majority of cells were 8 to 10 micrometers in diameter 
and had round to oval, darkly staining nuclei with clumped chromatin. Mitoses were 
variable and ranged from 0 to 6 per high power field. Fibrous connective tissue 
stroma varied from fine trabeculae to thick bands. Foci of necrosis and hemorrhage 
were irregularly distributed in the mass. Tumorous lymph nodes (Fig. 2) and hemal 
nodes were composed of diffuse sheets of large lymphocytes comparable to those in 
the thymic mass. Similar neoplastic cells were in the mucosa of the frontal sinus and 
cerebral meninges. Residual pituitary acidophils were identifiable among the 
neoplastic lymphoid cells in part of the meningeal mass. Follicular hyperplasia was 
common in lymph nodes and hemal nodes not effaced by tumor and in other 
lymphoid tissues including spleen, bronchus-associated lymphoid tissue, and gut-
associated lymphoid tissue. Subepithelial lymphoid follicular hyperplasia causing 
obstruction of bronchioles was found in areas of pulmonary atelectasis. 
Tumor samples collected at necropsy were analyzed by flow cytometry and 
the predominant cell type present in lymph node tumors was phenotypically 
identified as a CD2* CD4" CDS' lymphocyte. Very few cells with this phenotype 
were found in the blood, indicating the absence of leukemia with this 
lymphosarcoma. Circulating atypical lymphocytes were not detected by microscopic 
examination. 
Various tissue samples collected at necropsy were analyzed for infectious 
BIV and BLV by co-cultivation of tissue homogenates with FBL cells. BIV was 
recovered from the spleen; all other tissues were negative for both BIV and BLV. 
Bovine lymphosarcomas are generally classified into 4 groups: multicentric 
Thymic mass. Sheets of neoplastic lymphocytes subdivided 
by fine to moderate bands of dense fibrous connective 
tissue. Harris' hematoxylin and eosin stain. Bar = 240 /^m. 
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Figure 2. Thoracic lymph node. Large lymphocytes with indistinct 
cytoplasmic borders in a diffuse pattern effacing normal 
lymph node architecture. Cellular characteristics are similar 
to those in the thymic neoplasm. Harris' hematoxylin and 
eosin stain. Bar = 60 /xm. 
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lymphosarcoma associated with BLV infection in adult cattle, adult cutaneous 
lymphosarcoma, calfhood multicentric and calfhood thymic lymphosarcoma. This 
case of lymphosarcoma does not fit well into any of these classic syndromes. The 
calf was older than generally seen in the calfhood multicentric form, and liver, 
spleen, and bone marrow were not involved. Unlike the usual thymic form, 
numerous lymph nodes posterior to the diaphragm were also infiltrated. The 
case also does not fit the recently described familial form of thymic 
lymphosarcoma, in either the pattern of tumors or in the cell type involved.' This 
case, therefore, raises the possibility that BIV infection may, like HIV-1 and FIV 
infection, predispose animals to the development of atypical lymphosarcomas. 
The mechanisms responsible for the development of lymphomas in 
lentivirus infected animals and humans are unclear. A recent report raises the 
possibility that HIV may directly induce oncogene expression in a subset of 
lymphomas whether this mechanism occurs in BIV or other lentiviruses is 
currently unknown. Immunosuppression and the failure of immune surveillance 
are also believed to contribute to the induction of tumors by lentiviruses.' '' 
Chronic immune stimulation may also predispose to the development of 
mutations in immune cells.' " In this animal, immunosuppression does not appear 
to have been a major cause of tumor initiation, although it may have developed 
later as a consequence of the tumors. Lymphopenia and reduction of all 
lymphoqrte subsets were seen at day 190; however, there was no evidence for 
immunosuppression before the development of tumors. A slight decrease in y8 T 
cells and B cells was seen on day 112, prior to the onset of clinical signs; the 
significance of this is unknown. Immune function parameters measured included 
neutrophil function, monocyte function, and lymphocyte blastogenesis. All 
neutrophil and monocyte function tests in this calf (including tests of 
phagocytosis, migration, and cytotoxicity) were normal both before and after the 
onset of clinical signs. Lymphocyte blastogenesis was, however, increased in 
response to phytohemagglutinin (PHA), Pokeweed mitogen (PWM) and/or 
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concanavalin A (ConA) on all dates examined. There was no evidence of 
opportunistic infections. 
In this calf, therefore, chronic immune stimulation may be a more likely 
contributor to the development of lymphosarcoma. Follicular hyperplasia seen in 
early stages of BIV infection in this and other cases as well as enhanced 
lympho(^e blastogenesis, lend support to this hypothesis. In an interesting 
parallel, Callanan et. al. ' have reported the development of a multicentric B cell 
lymphosarcoma in a young cat experimentally infected with FIV. The tumor in 
this cat was presumed to arise as the result of B cell activation during FIV 
infection. Similarly, lymphosarcoma in the calf in this report could potentially 
have originated from a T cell infected or activated by BIV. The target cell(s) for 
BIV are currently unknown, although virus can be recovered from unfractionated 
mononuclear cells and from isolated monocytes. It is intriguing that, in this calf, 
tumor cells were immature T cells, with a CD2^ CD4' CDS" phenotype. 
The atypical nature of this lymphosarcoma, the absence of BLV, and the 
presence of replicating BIV, suggest that BIV infection may have predisposed 
the calf to the development of lymphosarcoma. Case studies or experiments on 
larger numbers of animals will be necessary to prove or disprove a causal 
relationship; however, this case does raise the possibility that some cases of 
atypical bovine lymphosarcoma may be associated with BIV infection. 
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GENERAL CONCLUSIONS 
From the results presented in this dissertation, it appears that BIV virus does 
ai^ect macrophage function. Treatment of normal monocytes with supematants from 
BlV-infected cells in vitro was shown to affect monocyte phagocytosis of opsonized 
Staphylococcus aureus, random and chemotactic migration, and ADCC function (1). 
The increases in phagoq^osis, random migration, and chemotaxis appear to be due 
to the BIV Gag protein (2). The molecule(s) responsible for the suppression of 
ADCC activity are not known, but do not appear to be Gag products (2). 
The effects of Gag on monocyte function are unexpected, but not 
unprecedented. The HIV p24 (capsid) protein was recently shown to affect 
macrophage responses to interferon (3), as well as the induction of lymphocyte 
proliferative responses to antigens (4,5). The effect of HIV p24 was traced to a 
conserved 7 amino acid peptide RGSDIAG (5). A homologous peptide, KTDEIIG, 
is present in a similar position (amino acids 239-246) in the p26 protein of BIV-R29 
(6). These two peptides are 71% homologous, when conservative amino acid 
substitutions are included in the analysis: there are 2 identical amino acids and 3 
conservative amino acid substitutions. In addition, a proline is present immediately 
5' to both peptides. The effects of the BIV peptide have not yet been tested on 
immune function, and other epitopes of the BIV Gag proteins may be responsible 
for the effects of BIV on chemotaxis and phagocytosis. Nevertheless, it is intriguing 
that this particular amino acid sequence has been conserved between the Gag 
proteins of BIV and HIV, particularly as the overall amino acid homology between 
these proteins is only 48-55%, when conservative amino acid substitutions are 
included (6). 
Immunomodulatory effects have not been reported for the Gag proteins of 
lentiviruses other than HIV or BIV, and most of the research on HIV p24 effects is 
relatively recent. It is not surprising that the effects of these proteins on immune 
function have not been studied. The Gag (core) proteins are located beneath the 
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envelope of mature retroviral virions; due to this structural position, they appear to 
be unlikely candidates for immunomodulatory agents. The Gag proteins are, 
however, also one of the major proteins produced in infected cells (7,8), and 
circulating Gag antigens may be found in the blood in some lentivirus infections 
(9,10). As BIV and HIV Gag proteins (3-5) both affect monocyte function, it is 
quite likely that Gag proteins from lentiviruses other than HIV and BIV can also 
affect immune functions. 
The Gag proteins of BIV and HIV share a common structural role and 
might, therefore, be expected have similar effects on the immune system. This does 
not, however, appear to be the case for either monocyte phagocytosis or chemotaxis. 
Direct in vitro treatment of macrophages with HIV virus suppresses phagocytosis 
and chemotaxis (11-14); these effects appear to be mainly due to envelope and 
transmembrane protein interactions (11,12,14,15) and not to gp24 (12,15). In 
contrast, direct treatment with BIV virus increased phagocytosis, random migration, 
and chemotaxis in our studies, and these effects appeared to be mediated by the 
BIV Gag protein(s) (1,2). Although both HIV (16,17) and BIV appear to suppress 
ADCC function, the mechanism for this effect has not been determined for either 
virus. Data is not available on the effects of other lentiviruses on macrophage 
function in vitro', however, the early in vivo effect of FIV appears to be an 
enhancement of antimicrobial function (18). In this respect, FIV appears to mimic 
the effects of BIV seen in vitro, rather than HIV. 
BIV and HIV viruses also appear to have very different effects on monoqrte 
function in vivo. HIV infection suppresses monocyte chemotaxis and phagocytosis in 
vivo (14,15,16,19-22); however, the only consistent effect of BIV infection in 
experimentally infected animals was a tendency (P = 0.06) for the suppression of 
phagocytosis during the first 4 to 8 months PI (1). During the last 2 years monocyte 
function in these animals was studied, monocyte function appeared to be entirely 
normal (1). One other study was published, during the course of this project, 
describing monocyte function in BIV infected animals (23). In this study, three 
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sequentially infected animals were examined for monocyte function defects early in 
infection and monocyte chemiluminescence, chemotaxis, and phagocytosis of latex 
particles were found to be suppressed. Our studies in infected animals are consistent 
with the report of decreased monocyte phagocytosis, but do not confirm that 
chemotaxis is suppressed (1). 
Finally, the functional changes seen in monocytes treated with BIV in vitro 
were not seen in monocytes from the infected animals. In fact, BIV enhanced 
monocyte phagocytosis and migration in vitro, but tended to suppress monocyte 
phagocytosis (but not affect chemotaxis, ADCC or random migration) for a few 
months in vivo (1). The difference between these in vivo and in vitro results may be 
a result of differences in the amount of Gag that monocytes are exposed to in vivo 
and in vitro. Production of the R29 virus in vivo is probably fairly low, as a low 
percentage of leukocytes appear to be infected in the blood (24). Circulating virus 
proteins in the blood, including Gag, would be expected to be correspondingly low. 
Furthermore, infection in vivo may also result in alterations in cytokine production, 
or other effects which overwhelm any effect of low levels of Gag. Slight increases in 
phagocytosis and migration induced by low levels of Gag could easily be masked by 
such effects. The early effects of BIV infection seen by Onuma et al (23) may also 
have been due to the induction of cytokines such as interferon. Currently, it is not 
known whether the effect of BIV on ADCC function in vitro is due to induction of 
Qftokines, to other cellular molecules such as prostaglandin Ej, or to a virus protein 
other than Gag. 
One final consideration is whether BIV (or Gag) production in the tissues is 
at sufficiently high levels to affect tissue macrophage function. Production of the 
related (25) HIV virus does appear to be upregulated in the tissues, as compared to 
the blood (26,27). The corresponding information is not available for BIV infection; 
however, there is evidence for the production of BIV Gag in lymph nodes (28). It is, 
therefore, possible that macrophage function is altered in the tissues, without effects 
on blood monocytes. It is not known whether alterations in tissue macrophage 
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function, particularly local suppression of ADCC, had any part to play in the 
unusual lymphosarcoma seen in one of the experimentally infected calves in this 
project. In this calf, blood monocyte function did not appear to be abnormal (29); 
however, tissue macrophages may have been affected without such alterations being 
reflected in blood monocyte function. The persistent monocytosis seen in this calf is 
occasionally seen with tumors (30); yet it is tempting to speculate that it may have 
been more than a nonspecific response to inflammation, in this animal. The finding 
that BIV may affect monocyte functions also raises the possibility that BIV might 
also affect the function of other immune cells such as natural killer cells and Tc 
cells, which appear to have greater importance in cancer immunosurveillance. 
Further research is necessary to determine whether BIV Gag affects leukocytes 
other than monocytes. 
Additional research is also necessary to determine whether the newer isolates 
of BIV (31) affect macrophage function identically to the R29 virus. These viruses 
could not be examined in the current study, as they are not easily grown in cell 
culture. However, recombinant proteins based on their Gag sequences might be 
constructed and examined for effects on macrophage function. At present, it is not 
known which portion of the BIV Gag proteins affect macrophage function 
(although, from the effects of the recombinant Gag, the active factor appears to 
reside either in, or close to, the p26 capsid protein). If this information becomes 
available, the newer lentiviruses could also be examined for sequence similarities or 
differences in this/ these areas of the genome. 
At the time this project was begun, BIV had been proposed as a model for 
AIDS. During the course of this study, it was found that neither the in vivo nor the 
in vitro effects of HIV and BIV in macrophages appear to be the same. 
Furthermore, published studies of the effect of BIV on other leukocytes have 
demonstrated only subtle alterations in cell function (32,33). The only direct 
parallels to HIV infection which have been found are follicular hyperplasia in lymph 
nodes (24,34), and production of virus proteins within lymph nodes (28). Whether 
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BIV (like HIV) causes clinical immunodeficiency, however, remains to be 
determined. Studies have not reported clinical immunodeficiency in animals 
experimentally infected with several different isolates of BIV (1,23,24,31-35) This 
does not, however, prove that clinical immunodeficiency could not be seen under 
other conditions, such as concurrent disease or physiologic stress, which might 
activate BIV virus. Most experimental studies on BIV infection have examined 
short-term infections of several weeks or months; our study on the long-term effects 
of BIV (of which these experiments were a part) appears to be unique. The effects 
of BIV infection on the induction of lymphosarcoma also remain to be explored. 
Finally, the value of research on BIV does not rest on solely on the discovery of 
similarities to HIV. The discovery that Gag affects macrophage function in both 
BIV and HIV (3-5) demonstrates how intriguing parallels may be found between 
lentivinises that, in other respects, appear to be dissimilar. 
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APPENDIX A; MACROPHAGE FUNCTION ASSAYS 
Monocyte phagocytosis and antibody-dependent cell-mediated cytotoxicity 
(ADCC) assays were developed as modifications of previously published assays of 
neutrophil function (1). Assays were optimized by varying the reagent 
concentrations, changing incubation conditions and increasing incubation times. The 
blind well chamber chemotaxis assay is a modification of procedures used for 
human and mouse macrophages (2,3); the primary alterations in this assay were 
changes in incubation times and the use of different chemoattractants, as bovine 
leukocytes do not appear to have receptors for the bacterial fMLP (N-formyl-
methionyl-leuqrl-phenylalanine) peptide. This appendix describes the monocyte 
assays in greater detail than is presented in the materials and methods sections of 
the research papers. Additionally, the results of monocyte function assays in BIV-
infected animal #808 are presented. 
Isolation of Bovine Monocytes 
Reagents: 
1) 75 cm^ tissue culture flasks (Coming Co., Coming, NY) 
2) Siliconized glass centrifuge tubes, 25 ml and 50 ml 
3) Erythrocyte lysing solution (1) 
4) Restoring solution (1) 
5) Hanks balanced salt solution (Gibco Laboratories, Chagrin Falls, OH) 
6) RPMI 1640 (Gibco Laboratories, Chagrin Falls, OH) with 10% fetal calf serum, 
100 U/ml penicillin, and 100 /xg/ml streptomycin (37°C) 
7) RPMI 1640, plain (37°C) 
8) Warm (37°C) phosphate buffered saline, pH 7.2 (PBS) 
9) Medium M199 (Gibco Laboratories, Chagrin Falls, OH) with 10% fetal calf 
semm, 100 U/ml penicillin, and 100 /xg/ml streptomycin 
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Procedure: 
1) Collect 225 ml whole blood into acid citrate dextrose anticoagulant (1) and 
centrifuge at 1500 x g for 30 minutes. Remove 12 ml buffy coat (approximately 1-5 x 
10* mononuclear cells, with some neutrophil and erythrocyte contamination) into a 
50 ml siliconized glass centrifuge tube. 
2) Lyse the erythrocytes by adding 24 ml of cold (4°C) lysing solution for 1 minute, 
then add 12 ml restoring solution. Centrifuge cold (4''C) for 15 minutes at 100 g, 
and discard the supernatant. Some cell pellets will still contain erythrocytes, but the 
majority of the cells should be leukocytes. 
3) Resuspend the cell pellets and wash the cells once at 100 x g for 15 minutes in 
Hanks balanced salt solution. Discard the supernatant. 
4) Add 25 to 30 ml of RPMI 1640 with 10% fetal calf serum (PCS) and antibiotics 
to each tissue culture flask. Incubate the flasks in a 37° C, 5% COj humidified 
incubator for 15 to 30 minutes (this step can be done while cells are being 
centrifuged), then add the cell pellet from one animal to each flask. 
5) Incubate the flasks in a 37°C, 5% COj humidified incubator for 1.5 hours. 
6) Wash the adherent cells 5 times (with a 12 ml pipette) with warm (37®C) RPMI 
medium (plain), then once with warm PBS. Before the first wash, vigorously shake 
the flasks (side to side) to resuspend loosely adherent cells. Remove this medium, 
then pipette approximately 12 ml fresh RPMI medium onto the cells, shake the 
flask lightly, and discard the medium. Repeat 4 more times. The medium from the 
last wash should be clear. 
7) Add 12 ml warm (37°C) PBS to each flask and incubate the flasks in a 37®C, 5% 
CO2 humidified incubator for 45 minutes. Every 10-15 minutes, gently tap the sides 
of the flasks to dislodge the cells. 
8) At the end of the 45 minute incubation, collect the PBS, with the cells which 
have detached, in a 25 ml siliconized glass centrifuge tube, and centrifuge for 15 
minutes at 100 g. Discard the supernatant, and resuspend the cells in the small 
amount of PBS which remains in each tube (approximately 100 - 500 /tl) by 
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vortexing gently. 
9) Remove a small sample of the cell pellet to count the cells (10 fd cell sample in 
70 III PBS works well). Resuspend the cells in M199 with FCS and antibiotics at the 
desired concentration (usually 2- 5 x 10® cells/ml). 
Phagocytosis Assay > Ingestion of Staphylococcus aureus 
Principle: 
This assay measures the specific ingestion of heat-killed, radioactively 
labelled Staphylococcus aureus which has been opsonized with anti-5. aureus 
antibody. After ingestion of bacteria by monocytes, extracellular S. aureus are lysed 
with lysostaphin, and the radioactivity associated with internalized bacteria is 
measured. 
Reagents: 
1) iododeoxyuridine labeled Staphylococcus aureus (1) 
2) Bovine anti- Staphylococcus aureus serum (1) diluted 1:10 in Earles balanced salt 
solution (Gibco Laboratories, Chagrin Falls, OH) 
3) Medium M199 (Gibco Laboratories, Chagrin Falls, OH) with 10% fetal calf 
serum, 100 U/ml penicillin, and 100 ng/wii streptomycin 
4) Cold (4°C) phosphate buffered saline (PBS) 
5) Lysostaphin (Sigma Chemical Co, St. Louis, MO); 1 unit/ml in PBS 
6) 12 x 75 mm polystyrene tubes (Becton-Dickinson Labware, Lincoln Park, NJ) 
Procedure: 
Preparation of samples 
Place in duplicate 12 x 75 mm plastic tubes: 5.0 - 10,0 x 10^ monocytes in 350 
III medium M199 with 10% fetal calf serum (FCS) and 100 U/ml penicillin, and 100 
/ug/ml streptomycin (bacteria:monocyte ratio of approximately 50:1 to 150:1, 
depending on the cell concentration chosen). Add monocytes to sterile sample tubes 
116 
at least 1 hour prior to assay, to allow monocytes to adhere to tubes. 
Preparation of standard and background tubes (2 each'): 
Add 350 fil M199 with 10% PCS and 1% penicillin/ streptomycin per tube. 
Assay 
1) At the start of the assay, add to all tubes: 
25/il of iododeoxyuridine labeled S. aureus 
50 ^ 1 of a 1:10 dilution of bovine anti-5. aureus serum 
2) Incubate tubes for 6 hours in a 37°C 5% CO2 humidified incubator. This assay 
can also be done overnight (12-16 hours), using 50 fjil of S. aureus per tube. 
3) Vortex briefly to resuspend unphagocytosed S. aureus. 
4) Add 0.5 ml of phosphate buffered saline (PBS) containing 1 unit/ml of 
lysostaphin to sample and background but not standard tubes. Incubate for 30 
minutes in a 37°C shaking water bath, to lyse unphagocytosed S. aureus. 
5) Add 2.0 ml cold PBS to sample and background tubes to stop the lysostaphin 
reaction. 
6) Wash cells by centrifugation at 1250 x g at 4°C for 10 minutes. 
7) Remove supernatant by aspiration, and discard into radioactive waste. 
8) Wash cell pellets one additional time by cold centrifugation with 2.0 ml cold PBS. 
9) Remove supernatant by aspiration, and discard into radioactive waste without 
disturbing the cell pellet. 
10) Determine the remaining radioactivity for standard, background, and sample 
tubes in a gamma counter set for iodine. Results = average of 2 replicates. Percent 
ingestion = ((cpm in sample tube) - (cpm in background tube)) -j- ((cpm in 
standard tube) - (cpm in background tube)) x 100. 
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Antibody>Dependent Cell-Mediated Ototoxicity (ADCC) 
Principle: 
Antibody-dependent cell-mediated cytotoxicity is measured as the percent 
specific lysis of ®'Cr-labelled chicken erythrocytes (cRBC) coated with a 
subagglutinating dose of bovine anti-cRBC antibodies. Lysis of cRBC releases ^'Cr 
into the medium; cell supematants are collected and the amount of released ^'Cr is 
determined. 
Reagents: 
1) Sterile 96-well round bottom microtiter plate - at least 300 /tl capacity per well 
(Becton-Dickinson Labware, Lincoln Park, NJ) 
2) Chicken erythrocytes (cRBC) standardized to 12,5 x 10® cells/ml in phosphate 
buffered saline. 0.5-1 ml of blood is collected with a heparinized syringe from 
a healthy chicken and stored in an equal volume of Alsievers solution at 4°C 
for up to 2 weeks. This cRBC stock is diluted to 12.5 x 10® cells/ml in PBS. 
Diluted cRBC may be stored up to 2 weeks at 4°C, or until spontaneous lysis 
of erythrocytes is observed. 
3) Bovine anti-cRBC serum diluted in M199. Preparation of bovine anti-cRBC 
serum has been previously described (1). The dilution of each lot of anti-
cRBC serum must be standardized for the ADCC assay; with the current lot, 
a dilution of 1:10 is optimal for monocytes and macrophages. 
4) 0.1 % Triton X in distilled HjO 
5) Medium M199 (Gibco Laboratories, Chagrin Falls, OH) with 10% fetal calf 
serum, 100 U/ml penicillin, and 100 yig/mX streptomycin 
Procedure: 
Radioactive labelling of cRBC 
Add 1 ml of diluted cRBC to a 15 ml conical centrifuge tube, with 12-14 ml 
PBS. One ml of cRBC will prepare one 96-well plate. Centrifuge for 10 minutes at 
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300 g, discard the supernatant, and resuspend the cRBC pellet in 0.3-0.5 ml M199 
with 10% FCS, 100 U/ml penicillin, and 100 fig/ml streptomycin. Add 50 nCi of 
sodium chromate (Amersham, Arlington Heights, IL) and incubate overnight in a 
37°C, 5% CO2 humidified incubator. The amount of sodium chromate may be 
increased up to 200 nCi with shorter incubation times. (Shorter incubation times will 
result in higher backgrounds for the assay.) 
Wash labelled cRBC 2 times with 12-14 ml PBS, by centrifiigation for 10 
minutes at 300 g. Discard the supernatant into the radioactive waste. Resuspend 
labelled cRBC in 10 ml M199 with 10% FCS, 100 U/ml penicillin, and 100 tig/nil 
streptomycin. 
Assav 
1) Sample wells: Dilute monocytes at 3.5-5,0 x 10® cells/ml in medium M199 with 
10% FCS, 100 U/ml penicillin, and 100 ng/ialL streptomycin. Aliquot monocytes to 
duplicate wells of a sterile 96 well plate at 100 ^1 per well and allow the cells to 
adhere (30 minutes to overnight). 
2) Add (per duplicate or triplicate wells): 
a) for standards: 150^1 0.1 % Triton X in distilled water 
b) for background wells: 50 ^1 anti-cRBC antibody and 100 /tl M199 with fetal 
calf serum and antibiotics. 
d) for sample wells: 50 n\ anti-cRBC antibody to the 100 fd of monoQftes. 
3) Add to all wells: 100 ^1 *'Cr labelled cRBC 
4) Incubate for 6 hours in a 37° C 5% CO2 humidified incubator, with no lid on the 
plate. 
5) Harvest supernatant with a filter harvesting system (Skatron Inc, Sterling, VA) or 
centrifuge at 300 x g for 10 minutes, then remove 150 /xl of the supernatant and 
transfer to tubes. 
6) Count supernatant in a gamma counter set for chromium 51. Results = average 
of 2 replicates. ADCC = [((cpm in sample wells) - (cpm background)) -r ((cpm in 
standard wells) - (cpm background))] x 100. 
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Random and Chemotactic Migration 
Principle: 
In the chemotaxis assay, monocytes migrate from the top chamber of a blind 
well chamber through a fiher toward a chemoattractant placed in the bottom well of 
the chamber. In the random migration assay, medium is placed in the bottom of the 
blind well chamber, and the spontaneous migration of monocytes is measured. With 
a polycarbonate filter and relatively short incubation times, migrated monocles can 
be found on the lower surface of the filter. The number of monocytes which have 
migrated is measured by staining the filter and counting monoqrte numbers under a 
microscope. 
Reagents: 
1) 48-well microchemotaxis chamber (Neuroprobe, Rockville, MD) 
2) 5.0 /X pore size polycarbonate filters for chamber (Nucleopore, Pleasanton, CA) 
3) Medium M199 (Gibco Laboratories, Chagrin Falls, OH) with 10% fetal calf 
serum, 100 U/ml penicillin, and 100 /xg/ml streptomycin 
4) Chemoattractant: 
Chemotaxis: 10% zymosan activated serum (1) in medium M199 with 10% 
FCS and antibiotics. 
Random migration: Medium M199 with 10% FCS and antibiotics. 
5) Diff Quik stain (American Scientific Products, Columbia, MD) 
Procedure: (run wells in duplicate) 
1) Add 26 /jlI chemoattractant or medium, per well, to bottom chamber wells. The 
chemoattractant or medium should be vortexed briefly, prior to use, to prevent the 
later formation of air bubbles within the chamber. 
2) Insert a filter, and assemble the blind well chamber. 
3) Incubate blind well chamber in a 37° C 5% CO2 humidified incubator for 30 
minutes to equilibrate the solutions, with a slide over the chamber to prevent 
120 
evaporation. 
4) Add macrophages : 25-50 pH per chamber of a 2.0 to 5.0 x 10® macrophage/ml in 
M199 with 10% FCS and antibiotics. Do not use antimycotics in the migration 
medium, as they inhibit migration. 
5) Incubate for 1.5 hours in a 37° C 5% CO2 humidified incubator. 
6) Remove the filter, and scrape cells off the top (unmigrated) edge of the filter, 
using the edge of a glass slide or other cell-scraping apparatus. Stain the filter with 
a modified hematoxylin-eosin stain (Diff Quik) stain. 
7) Examine the filter with the oil immersion objective of a light microscope -
determine the number of cells per 2-10 high power fields (hpf) per sample. Two 
high power fields can be counted if cells are evenly distributed across the filter; 
more fields may need to be counted if the cell distribution is uneven or cell 
numbers are low (less than 15-20 cells/ high power field). Migration = cells/hpf 
(average of 2 replicates). 
Monocyte Function Assays 
Animal #808 
Animal #808 is a Holstein steer infected with 1.3 x 10* syncytium forming 
units of monocyte-derived BIV virus (R29 strain) from a calf with lymphosarcoma 
(4,5). BIV virus has been consistently isolated from the monocytes of animal #808 
for the first 2.5 years post-inoculation (PI). Monocyte function assays were repeated 
every 2-4 weeks PI, starting at 5 weeks PI and continuing for the next 6 months. The 
function of monocytes from animal #808 was compared to three retrovirus-negatlve, 
age matched Holstein calves. As seen in table 1, there was no consistent significant 
(P < 0.05) difference between functional assays in animal #808 and the three 
control animals. (The occasional significant (P < 0.05) differences from the controls 
are not unexpected, when a large number of statistical comparisons have been 
made.) 
It is interesting, however, to note that monocytes from calf #808 had 
Table 1: Monocyte function in calf #808, compared to three age, sex and breed matched controls. 
Weeks 
PI 
Staphylococcus aureus 
Ingestion 
Controls 808 
(Mean ± SD) 
ADCC 
Controls 
(Mean ± SD) 
808 
Random Migration 
Controls 808 
(Mean ± SD) 
Chemotaxis 
Controls 808 
(Mean ± SD) 
5 12 ± 9 25 26 ± 18 33 NA NA NA NA 
13 16 ± 6 21 5 2 + 7  18* 8 ± 6 5 38 ± 18 26* 
14 28 ± 7 31 NA NA 17 ± 12 23 35 ± 18 56 
18 22 ± 3 25 19® 11 7® 5 64® 40 
19 NA NA NA NA 14 ± 6 8 67 ± 16 51 
21 28 ± 2 27 NA NA 17 ± 14 18 46 ± 28 67 
27 18 ± 12 22 37® 35 7® 11 39® 52 
27 17 ± 1 20* 12 ± 3 
• 
5 NA NA NA NA 
31 32 ± 2 33 10 ± 6 4 15 ± 7 3 96 ± 51 70 
33 NA NA 16 ± 10 11 32 ± 2 10* 84 ± 12 37* 
35 37 ± 4 32 NA NA 15 ± 9 19 65 1 2 72* 
Values marked with an asterisk (*) are at least 2 standard deviations different from the mean for the control 
animals, on that date. For controls, n = 3, except data marked with ®, where values were only available from 2 
animals, and no standard deviation can be computed. Abbreviations: SD = standard deviation. NA = data not 
available. 
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consistently lower ADCC function (on 6 of 7 dates), and higher Staphylococcus 
aureus ingestion (on 7 of 9 dates) than the mean for the 3 control animals, even 
though this was not statistically significant. These observations are consistent with 
the effect of BIV on normal macrophage function in vitro (4,6); however, it is also 
possible that calf #808 had a natural tendency to have higher than average 
phagocytic function and lower than average ADCC function, unrelated to his BIV 
infection status. No patterns were visible for random and chemotactic migration of 
monocytes from calf #808. 
References 
1. Roth, J.A. and M.L. Kaeberle. 1981. Evaluation of bovine polymorphonuclear 
leukocyte function. Vet. Immunol. Immunopathol 2:157. 
2. Smith, P.D., K. Ohura, H. Masur, H.C. Lane, A.S. Fauci, and S.M. Wahl. 1984. 
Monocyte function in the acquired immunodeficiency syndrome: defective 
chemotaxis. J. Clin. Invest. 74:2121. 
3. Martin, L.S., TJ. Spira, S.L. Orloff, and R.C. Holman. 1988. Comparison of 
methods for assessing chemotaxis of monoc3rtes and polymorphonuclear leukocytes 
isolated from patients with AIDS or AIDS-related conditions. J. Leuk. Biol 44:361. 
4. Rovid, A.H., S. Carpenter, and J.A. Roth. 1995. Monocyte function in cattle 
experimentally infected with bovine immunodeficiency-like virus. Vet. Immunol 
Immunopathol 45:31. 
5. Rovid, A.H., S. Carpenter, L.D. Miller, K.P. Flaming, M.J. Long, M.J. Van der 
Maaten, and J.A. Roth. An atypical T cell lymphosarcoma in a calf with bovine 
immunodeficiency-like virus (submitted for publication). 
6. Rovid, A.H. and J.A. Roth. Enhancement of monocyte migration and 
phagocytosis by bovine immunodeficiency-like virus Gag proteins (submitted for 
publication). 
123 
APPENDIX B: RESPONSES OF CULTURED BOVINE MONOCYTES TO 
BOVINE ALPHA AND GAMMA INTERFERON 
This is the text and graphs from a poster presented at the 70th Conference of 
Research Workers in Animal Disease (1990). 
Abstract 
Bovine blood monocytes were isolated by adherence to plasma-coated tissue 
culture flasks and cultured for 1 to 5 days to determine whether time in culture 
affects the responsiveness of monocytes to interferons. On days 1, 2 and 4 of 
culture, aliquots of monocytes were removed, treated for 15 hours with recombinant 
bovine alpha or gamma interferon, and the following function assays performed: 
random migration, chemotaxis, antibody-dependent cell cytotoxicity (ADCC) and 
antibody-independent cell cytotoxicity (AICC). Chicken erythrocytes were used as 
target cells in cytotoxicity assays. Some but not all monocyte functions changed with 
time in culture. Both random and chemotactic migration decreased by the fifth day 
in culture. Variable responses to interferon treatment were seen, depending on the 
particular assay performed. Most animals consistently responded to both alpha and 
gamma interferon with decreased random and chemotactic migration on all 3 days; 
however, not all animals had increased ADCC activity in response to interferon. 
Some monocytes which were initially unresponsive to interferon in ADCC assays 
became responsive with increased time in culture. AICC was only occasionally seen 
in a few individuals and did not change with interferon treatment. According to 
these results, bovine monocyte responses to interferon may vary depending on the 
functional assay performed and may change with time in culture. 
Introduction 
Macrophage functions are modulated both by cytokines, particularly the 
interferons, and by the degree of macrophage maturity. Increased cytotoxicity, 
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increased expression of Fc receptors, and decreased cell migration are among the 
functions associated with interferon activation (1). The degree of monocyte maturity 
may influence the response to interferon. Although some of the responses of human 
and mouse interferons during aging in culture have been studied (2,3), few studies 
have been carried out on other species. We have, therefore, examined the responses 
of bovine monocytes to bovine recombinant alpha and gamma interferon during 
aging in culture. 
Materials and Methods 
Monocyte isolation and culture 
Bovine mononuclear cell fractions were isolated from the bu^ coat of 12 
healthy adult Holstein steers and the red cells lysed by flash lysis using distilled 
water. Tissue culture flasks were prepared by coating each flask with autologous 
plasma for 30 minutes, then adding culture medium consisting of RPMI 1640 (Gibco 
Laboratories, Chagrin Falls, OH) supplemented 10% fetal calf serum, and 
antibiotics (50 U/ml penicillin, 0.05 mg/ml streptomycin) to each flask; the final 
concentration of autologous plasma was 20%. The mononuclear cells from each 
animal were divided into 3 tissue culture flasks and incubated for 1 to 2 hours at 
39°C in a 5% CO2 humidified incubator. After incubation, the adherent cell 
populations were washed three times with warm RPMI 1640 containing 10% FCS 
and antibiotics. 
On days 1, 2 and 4, the monocytes from one flask were detached for each 
animal (4). The culture medium was removed, and the adherent cells washed once 
with warm phosphate buffered saline (PBS). The medium was replaced with fresh 
warm PBS and the cells incubated for 30 minutes at 39 °C, with occasional brief 
agitation. The detached cells were washed once at 120 x g for 15 minutes, and the 
cell numbers adjusted to 5.0 x 10® cells/ml in medium M199 (Gibco Laboratories, 
Chagrin Falls, OH) supplemented with 10% FCS and antibiotics. The monocytes or 
monocyte-derived macrophages were aliquoted into individual wells (ADCC) or 
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siliconized glass tubes (migration) and treated overnight (12-15 hours) with various 
concentrations of recombinant bovine Interferon alpha (lot 13/1035/1, gift of Ciba-
Geigy, Basel, Switzerland) or interferon gamma (lot AE62, gift of Ciba-Geigy, 
Basel, Switzerland) or medium alone. Functional assays were performed on days 2, 
3 and 5. 
Migration 
Random and chemotactic migration were performed in a 48-well blind well 
chamber (Neuroprobe, Rockville, MD) using 5.0 fim pore size polycarbonate filters 
(Nucleopore, Pleasanton, CA). Medium Ml99 or 10% zymosan activated serum 
were used as chemoattractants for random and chemotactic migration, respectively. 
All migration assays were performed in duplicate, using 2.5 x 10® monocytes or 
macrophages per well. Samples were incubated for 2 hours at 39°C in a 5% CO2 
humidified incubator. After 2 hours, the filters were stained with a modified 
hematoxylin-eosin stain (Diff Quik, American Scientific Products, Columbia, MD) 
and cells that had migrated to the bottom of the filter were counted in 10 high 
power fields. Results are expressed as the average number of cells per high power 
field for 2 replicates per animal. 
Cytotoxicity Assess 
Antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-
independent cell cytotoxicity (AICC) were performed in 96 well microtiter plates 
(Becton-Dickinson Labware, Lincoln Park, NJ): 2.5 x 10® monocytes or macrophages 
at a macrophage to target cell ratio of 20:1 were added to triplicate wells with or 
without anti-cRBC antibody. ®'Cr labelled chicken erythrocytes (cRBC) were used as 
target cells (5). Standard wells containing cRBC lysed with 0.1% Triton X in 
distilled water, and background wells containing cRBC with or without antibody and 
no added monocytes, were run on each plate. The plates were centrifuged at 400 x 
g for 5 minutes, then incubated at 39°C in a 5% CO2 humidified incubator for 6 
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hours. Tlie supernatant was harvested and the percent of radioactivity released from 
the labelled cRBC determined. Percent ADCC or AICC is defined as ((radioactivity 
in sample wells - radioactivity in background wells) (radioactivity in standard 
wells - radioactivity in background wells) x 100). 
Statistical Analysis 
Each animal served as its own control; interferon treated monocytes and 
macrophages were compared to control cells using an analysis of variance blocked 
by animal. All samples were included in the analysis for significance, independent of 
whether the animals were classified as responders or non-responders to interferon. 
Results 
Monocyte purity and viability 
Monocyte populations were at least 84% pure (average purity 93% ± 4%) by 
nonspecific esterase staining (6) and eosin-hematoxylin staining; the contaminating 
cells were mainly eosinophils and small lymphocytes. Viability by trypan blue 
staining was 93% ± 3%. 
ADCC 
In the ADCC assay, overall responsiveness to the interferons appeared to 
increase with time in culture (Figure 1); however, individual cattle were highly 
variable in their responsiveness to alpha or gamma interferon (figure 2). We have 
defined responders as cattle whose ADCC values increased to greater than 125% of 
the control value with interferon treatment. Responses up to 376% of control values 
were seen. Three animals remained responders on all 3 days examined and 3 
animals remained non-responders. In the remaining 6 animals, a trend was seen for 
increasing numbers of responders to interferon 7 and decreasing numbers of 
responders to interferon a, with longer time in culture. Additional experiments with 
larger numbers of animals would be necessary to confirm these observations. 
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•i CONTROL 
I I ALPHA INTERFERON 13,000 U/ml 
gamma INTERFERON 200 U/ml 
R?9i GAMMA INTERFERON 20 U/ml 
DAY 2 DAY 3 DAY 5 
DAYS IN CULTURE 
Figure 1: Means and standard errors for ADCC of control and interferon 
treated monocytes on days 2, 3 and 5 of culture (n = 12). a: value is 
significantly different from control at P < 0.05. b: value is different from 
control at P < 0.10. 
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Figure 2: Means and standard errors for ADCC function, with animals 
divided into groups of responders and non-responders to alpha or gamma 
interferon. Responder = ADCC (treated monocytes) ADCC (control) 
> 125%. 
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AICC 
AICC by bovine monocytes against cRBC has not been consistently seen in 
our laboratory in this or previous experiments. The AICC levels in this experiment 
were generally very low; most animals had values of less than 3%, although a few 
animals had control values of up to 25%. AICC values were not influenced by 
interferon treatment (figure 3). 
Migration 
All samples that had mononuclear phagocyte migration of at least 2 cells per 
high power field consistently responded to alpha and gamma interferon with 
decreased random and chemotactic migration (figures 4 and 5). This response was 
most pronounced with 200 U/ml of interferon 7, but decreased levels of migration 
inhibition were seen with 20 U/ml interferon 7 or 13,000 U/ml interferon a, 
Variability in migration was high, both between animals and on different days; 
however, in general, migration began to decrease on day 3 and reached low levels 
by day 5. For this reason, samples assayed on days 3 and 5 were less likely to reach 
statistical significance. By day 3, two thirds of the animals had low levels of control 
migration that could not be influenced by interferon, although the cells that did 
migrate were inhibited by interferon. 
Summaiy 
We have found that the responsiveness of bovine mononuclear phagocytes to 
bovine alpha and gamma interferon is variable and dependent on the particular 
function tested, the individual animal, and the length of time the monocytes have 
been in culture. Recombinant bovine interferon treatment increased ADCC function 
in both monocytes and monocyte-derived macrophages; however, this response was 
not seen in all animals. Animals could be classified into two groups for ADCC 
function: responders and non-responders. Macrophages from some animals 
consistently remained responders or non-responders during the culture period; 
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CONTROL 
I I ALPHA INTERFERON 13,000 U/ml 
^3 gamma interferon 200 U/ml 
f991 GAMMA INTERFERON 20 U/ml 
DAY 2 DAY 3 DAY 5 
DAYS IN CULTURE 
Figure 3; Means and standard errors for AICC of control and interferon 
treated monocytes on days 2, 3 and 5 of culture (n = 12). No values are 
significantly different from the control. 
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CONTROL 
f I ALPHA INTERFERON 13,000 U/ml 
RVi GAMMA INTERFERON 200 U/ml 
GAMMA INTERFERON 20 U/ml 
J. 
DAY 2 DAY 3 DAY 5 
DAYS IN CULTURE 
Figure 4: Means and standard errors for random migration of control and 
interferon treated monocytes on days 2,3 and 5 of culture. Migration for 
each animal is expressed as the average number of cells per high power 
field in 2 replicates (n = 11 on day 2; n = 9 on day 3; n = 9 on day 5). a: 
value is significantly different from control at P < 0.05. b: value is 
different from control at P < 0.10. 
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CONTROL 
ALPHA INTEKFERON 13,000 U/ml 
GAMMA INTERFERON 200 U/ml 
GAMMA INTERFERON 20 U/ml 
b b 
DAY 2 DAY 3 DAY 5 
DAYS IN CULTURE 
Figure 5: Means and standard errors for chemotactic migration of control 
and interferon treated monocytes on days 2,3 and 5 of culture. Migration 
for each animal is expressed as the average number of cells per high 
power field in 2 replicates (n = 11 on day 2; n = 9 on day 3; n = 9 on 
day 5). a: value is significantly different from control at P < 0.05. b: value 
is different from control at P < 0.10, 
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however, some cultwed macrophages appeared to gain responsiveness to interferon 
gamma and lose responsiveness to interferon alpha with longer time in culture. Both 
20 U/ml and 200 U/ml of recombinant bovine gamma interferon were equally 
effective in stimulating increased ADCC, independent of the length of time the 
monocytes had been cultured. 
In contrast to the animal variability found in the ADCC assay, macrophage 
random and chemotactic migration was inhibited by both recombinant bovine alpha 
and gamma interferon in most animals. Migration inhibition was most effective with 
200 U/ml of interferon 7, although a lesser degree of inhibition was seen with 20 
U/ml interferon 7 and 13,000 U/ml interferon a. The response to interferons did 
not appear to change with time in culture, although the numbers of migrating cells 
tended to decrease after 3 days in culture and migration inhibition thereafter 
became difficult to measure. 
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APPENDIX C; MACROPHAGE INFECTION WITH BIV IN VITRO 
Infection of macrophages with cell-associated but not cell-free virus 
BIV virus can infect a variety of primary bovine embryonic tissue explants, as 
well as canine thymocyte and embiyonic rabbit epithelial cell lines (1). In these 
systems, cell-free virus is able to infect cells, although infection does appear to be 
more efficient with cell to cell transmission (1). Therefore, attempts were initially 
made to infect bovine monoortes and monocyte-derived macrophages with cell-free 
virus (multiplicity of infection approximately 10"^ to 10'^ syncytium forming units of 
BIV per monocyte). These experiments were unsuccessful. Macrophages from 
several different animals, infected after different periods of time in culture, did not 
become infected. Both unstimulated cultures and cultures stimulated with 5 fig/ml 
of lipopolysaccharide resisted infection. There were a few cultures from which low 
amounts of BIV was recovered after long periods (greater than 1 month); however, 
these macrophage cultures also showed an overgrowth of resembling fibroblasts, 
which cast doubt on which cells were harboring the virus. 
It was later observed that these fibroblast-like cells are not able to proliferate 
in a serum free macrophage medium (macrophage-SFM) (Gibco Laboratories, 
Chagrin Falls, OH). This observation allowed us to infect macrophages without the 
potential for overgrowth by the fibroblast-like cells. Furthermore, it was found that 
fetal bovine lung (FBL) cells did not survive in macrophage-SFM medium. 
Therefore, an experiment was designed to infect macrophages by short-term co-
culture with BlV-infected FBL cells. Macrophages were established in culture in 
RPMI 1640 (Gibco Laboratories, Chagrin Falls, OH) with 10% fetal calf serum, 100 
U/ml penicillin and 100 ng/ml streptomycin. After 2-4 days, BlV-infected FBL cells 
were added to the culture. The cells were co-cultured for 1-2 days, then the medium 
was changed to macrophage-SFM. In some experiments, cultures were maintained 
for the entire period (from day 0) in macrophage-SFM. Control cultures, with 
normal macrophages and uninfected FBL cells, were established in parallel. FBL 
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cells disappeared by 11 to 20 days from the infected cultures, and more slowly from 
the uninfected cultures. Fibroblast-like cells were not seen. 
Slow death of macrophages occurred in the infected cultures and veiy few 
cells (in either of 2 cultures from different animals) were left at the conclusion of 
one 3 week experiment. Some of these infected macrophages had been passaged 
onto uninfected macrophages from the same animal; these macrophage cultures 
were also very sparse. FBL cells had disappeared from these particular cultures by 
day 11 of culture; the remaining cells were determined by visual observation (on day 
20) to be macrophages. Large quantities of virus were recovered from these few 
remaining macrophages by co-cultivation with FBL cells, in both cultures. FBL cells 
formed large numbers of BIV syncytia within 3 days of their addition to the infected 
macrophage cultures. Passage of the FBL cells was not necessary to recover the 
virus, indicating that a large quantity of virus was present. 
Staining of infected macrophages and other cells with antibodies 
to BIV Gag proteins 
Procedure 
Cultures were established from a variety of BlV-infected and uninfected cells, 
in 6 well plates (Becton-Dickinson Labware, Lincoln Park, NJ). These cells included 
canine thymocytes infected with BIV, uninfected FBL cells, FBL cells infected with 
BIV, macrophages from experimentally infected and control animals, and 
macrophages infected in vitro with BIV by co-cultivation. Infected and uninfected 
cell cultures were fixed with either cold (4°C) methanol or cold 70% acetone/ 30% 
methanol fixative, and washed for 10 minutes in Hanks balanced salt solution 
(Gibco Laboratories, Chagrin Falls, OH) or phosphate buffered saline. Prior to 
staining, wells were blocked with normal goat serum (Pierce, Rockford, IL). Fixed 
cultures were incubated for 30 minutes at room temperature with rabbit anti-Gag or 
control serum (2) diluted in Hanks balanced salt solution. The anti-Gag antibodies 
detect BIV core (Gag) proteins. Bound primary antibodies were detected by staining 
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with avidin/biotin horseradish peroxidase kits which detect rabbit IgG (Pierce, 
Rockford, IL). 
Results 
Initial experiments demonstrated that rabbit anti-Gag antibodies, but not 
control antibodies, specifically stained BlV-infected canine thymocytes at dilutions 
of 1:200 or 1:1000. BlV-infected (but not uninfected) FBL cells could also be 
specifically stained with 1:200 rabbit anti-Gag serum. Macrophages infected in vitro 
by co-culture also appeared to be specifically stained by antibodies to the Gag 
proteins. In macrophages infected by co-culture, some individual cells stained darkly 
with anti-Gag but not control sera at dilutions of either 1:100 or 1:200. In some 
cases, the stain was dark enough to obscure cellular details. 
Staining of macrophages from infected animals, however, yielded equivocal 
results. Individual macrophages in these cultures were not stained with either anti-
Gag or control antibodies, at dilutions of 1:100 or 1:200. Macrophage syncytia 
stained faintly at 1:200 and more strongly at 1:100 with anti-Gag serum. The pattern 
of staining in macrophage cultures from HIV-infected animals #808 and #342 
showed a relatively dark rim of stain around the periphery of the syncytia, a second 
area of dark staining in the center of macrophage syncytia (often surrounded by a 
halo of nuclei), and faint cytoplasmic staining. It is not clear, however, whether this 
staining was specific for BIV, as macrophage syncytia in uninfected cultures also 
stained, although more faintly, with anti-Gag antibodies. Light staining of syncytia 
was also seen with control antibodies. It appeared, therefore, that, at a dilution of 
1:100, rabbit (particularly anti-Gag) antibodies were binding nonspecifically to a 
macrophage protein which was concentrated at the edge and perinuclear areas of 
syncytia. Some of this staining may have been specific for Gag, as the stain was 
darker in infected than control cells; however, as Gag proteins could not be 
detected in macrophages from infected animals at a dilution of 1:200, it was 
concluded that either Gag antigens were not present in these macrophages, or the 
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staining was not sensitive enough to detect them. 
Summaiy 
From these experiments, it appears that macrophages can be infected with 
BIV virus, if macrophages are co-cultivated with infected cells. Onuma et al (3) 
were also successful in infecting bovine macrophages by co-culture with irradiated 
BlV-infected bovine embryonic spleen cells. Macrophage infection with cell free 
virus appears to be difficult, at least with the R29 virus under the conditions used in 
these experiments. It is possible that different incubation conditions, an alternate 
virus source, or a higher multiplicity of infection may result in successful infection 
with cell free virus. It is not clear why macrophages appear to be more difficult to 
infect with cell free virus than are primary bovine cell lines (1). It is possible that 
these embryonic cell lines contain higher levels of the (unknown) BIV receptor than 
do macrophages and monocytes. Alternatively, the R29 virus may have adapted so 
well to in vitro cell culture that it has lost its receptor for macrophages. The newer 
isolates of BIV do not readily infect primary embryonic cell cultures (4); it appears, 
therefore, that the second hypothesis is more likely to be true. Finally, it is possible 
that the natural mode of macrophage infection with BIV is by cell to cell contact. 
The BlV-related (5) lentivirus HIV can spread very quickly by cell contact, without 
the production of mature virions (6). It would not be surprising if this proves to be 
the most effective mode for BIV transmission, as well. 
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APPENDIX D; AN ANTIGEN CAPTURE ELISA FOR GAG p26 ANTIGEN 
Background 
Current methods for detecting BIV infected cells include direct staining for 
BIV Gag (core protein) antigens, detection of reverse transcriptase in cell 
supematants, detection of viral DNA by PCR, in situ hybridization for mRNA, and 
virus isolation by co-cultivation with fetal bovine lung (FBL) cells. Of these 
procedures, the only assay which can easily be used on large numbers of samples is 
the reverse transcriptase assay; all of the other assays are limited in the number of 
samples which can be tested at one time. Reverse transcriptase activity has not, 
however, been detected in macrophage cultures from BIV infected animals, 
including those which contain virus by co-cultivation with FBL cells. Consequently, 
an antigen capture ELISA was developed to detect viral antigens in supematants 
from BlV-infected macrophage cultures. The BIV p26 antigen was chosen as the 
target for detection, as the Gag proteins appear to be the major proteins produced 
in BlV-infected cell cultures (1), and the p26 protein also has less antigenic 
variability than the BIV envelope proteins (2). An additional consideration was the 
availability of both mouse monoclonal and rabbit polyclonal antibodies specific for 
the BIV Gag proteins. 
Principle 
BIV p26 antigen is captured by rabbit antiserum specific for the recombinant 
BFV protein Gag3. The bound antigen is detected with a mouse monoclonal IgG 
antibody against BIV p26, and an avidin-biotin/horseradish peroxidase detection 
system for mouse antibodies (Pierce, Rockford, IL). 
Reagents 
1) Immulon 4 ELISA plates 
(Dynatech Laboratories, Chantilly, VA) 
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2) Carbonate binding Buffer - pH 9.5 -9.7 
Add 0.159 g NajCOj and 0.293 gNaHCOj to 100 ml distilled H2O. Adjust the 
pH, if necessary, with HCl or NaOH. 
3) Wash solution - Phosphate buffered saline (pH 7) 
Stock solution (lOX): 
Working solution (0.01 M PBS/ 0.05% Tween wash solution): 
Dilute 400 ml lOX PBS stock solution with 3.6 liters distilled H2O and 
add 2 ml Tween 20. 
3) Blocker. 1% bovine serum albumin (Sigma Chemical Co., St. Louis, MO) in PBS 
with 0.05% Tween 20 
4) Antibodies 
Capture antibody: Polyclonal rabbit serum against the BIV Gag proteins was 
prepared by immunizing rabbits with a recombinant fusion protein (Gag3, provided 
by J. Isaacson). The Gag3 protein consists of the BIV p26 capsid protein, with small 
flanking regions of the nucleocapsid and matrix proteins, expressed as a trpE fusion 
protein (3). The optimum concentration in this ELISA for the serum collected 
10/22/92 is 1:800 in carbonate buffer. 
Detection antibody: The mouse monoclonal antibody against BIV p26 was 
prepared (4) and concentrated (5) as previously described. The optimal dilution for 
the 32X concentrate is 1:50 in Hanks balanced salt solution (Gibco Laboratories, 
Chagrin Falls, OH) with 1% fetal calf serum. 
5) Detection system: Avidin-biotin horseradish peroxidase kit for mouse IgG (Pierce, 
Rockford, IL). The avidin-biotin system is available as a kit which has been 
optimized for the detection of mouse IgG. For this ELISA, a biotin-labelled rabbit 
anti-mouse IgG antibody (Pierce, Rockford, IL) (1:400 in Hanks balanced salt 
monobasic NaH2P04.H20 
dibasic Na2HP04 
NaCl 
H2O 
13.2 g 
43.2 g 
340.0 g 
4 liters 
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solution) has been substituted for the horse anti-IgG provided in the kit, to reduce 
background staining. 
6) Substrate'. TMB-ELISA solution (Gibco Laboratories, Chagrin Falls, OH). TMB 
= 3,3',5,5'- Tetramethylbenzidine dihydrochloride. 
7) Stop solution for TMB: 1 N H2SO4 in distilled water 
8) Test antigens for assay development'. 
recombinant BIV Gag3 fusion protein (3), provided by J. Isaacson 
recombinant trpE portion of the Gag3 fusion protein (control) (3) 
supernatants from fetal bovine lung (FBL) cells infected with BIV 
Procedure 
Pre-treatment of cell supernatants 
Cell supernatants do not show detectable p26 antigen unless they are treated 
with 2% Nonidet P40 (Sigma Chemical Co, St. Louis, MO) to lyse virions. 
1. Prepare plates by binding capture antibody 
Bind polyclonal anti-Gag antibody to ELISA plate(s) (100 n\ per well; 1:800 
in carbonate binding buffer) overnight at 4°C. Wash 5 times with PBS/Tween wash 
solution (250-300 fil/ well). 
2. Block plates 
Add blocker (150 ^1 1% bovine serum albumin in PBS/Tween) to all wells. 
Incubate at 37°C for 45 minutes, then wash 5 times with PBS/Tween wash solution. 
3. Bind samples 
Add samples or standards (in duplicate) at 100 ^1/ well, and incubate at 
37°C for 45 minutes. Wash 5 times with PBS/Tween wash solution. 
4. Detect bound antigen 
Add 100 fil biotin-labelled rabbit anti-mouse IgG (diluted 1:400 in PBS or 
Hanks balanced salt solution) per well. Incubate at 37°C for 45 minutes, then wash 
5 times with PBS/Tween wash solution. Add 50 ^1 avidin/biotin/horseradish 
peroxidase complex (see kit for instructions), and incubate at 37°C for 45 minutes. 
Wash 6 times with PBS/Tween wash solution. 
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5. Substrate 
Add 100 /il TMB solution, and incubate for 25 minutes at room temperature. 
At the end of the incubation, add stop solution (IN H2SO4) at 25 /d per well. 
6. Read plate: Read plates at 450 run wavelength on an ELISA reader. 
Parameters examined during assay development 
Optimal antibody concentrations 
Monoclonal anti-p26 antibodies were tested at dilutions of 1:10 to 1:320, and 
polyclonal anti-Gag rabbit antibodies at 1:200 to 1:12800. The optimal concentration 
was defined as the most dilute concentration of antibody which gave OD (optical 
density) readings equal to or higher than other antibody concentrations. 
An irrelevant mouse monoclonal antibody (IgG specific for 75 T cells) was 
used to demonstrate that the anti-p26 mouse monoclonal was not binding non-
specifically: OD values for the irrelevant monoclonal antibody were identical to 
wells with no antigen. Control rabbit antibodies (generated against the TrpE vector) 
did not bind BlV-infected FBL cell supernatants (OD values; 0.44, anti-Gag 
antibodies with BIV supernatants; 0.25, anti-trpE antibodies with BIV supernatants; 
0.25-0.28, wells with control supernatants (no antigen) and either anti-trpE or anti-
Gag antibodies). 
Blockers 
Several blocking solutions were tested, using recombinant Gag protein 
(Gag3) at 0.25 or 2.5 ng/m\ as the antigen. The results from 2 dates, for 2.5 /Kg/ml 
recombinant Gag, are shown in table 1. Most blockers performed adequately; 1% 
bovine serum albumin (BSA) appeared to consistently have a slightly higher signal 
to background ratio than other blockers. Blotto blocker (2% powdered milk, 1% 
Triton XlOO, 50 mM Tris HQ (pH 8,5), 0.05% Tween 20, and 10 mM EDTA in 
PBS) was consistently poor. Gelatin gave erratic results, and was often a poor 
blocker. 
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Table 1: The effect of different blockers on detection of p26. 
Experiment 1 Experiment 2 
Blocker Signal/Background 
Ratio 
Blocker Signal/Background 
Ratio 
Powdered milk Bovine serum albumin 
(1%) 
9.4 
4% 5.0 Powdered milk (0.5%) 6.8 - 7.6 
2% 5.4 Blotto 6.1 
1% 5.0 Casein (1%) 8.5 
0.5% 5.8 Superblock 8.2 
Bovine serum albumin 
4% 5.2 
2% 5.2 
1% 6.1 
0.5% 5.7 
Blotto 4.5 
Gelatin (2%) 6.2 
Signal/ Background ratio = the OD for 2.5 ^ig/ml recombinant GagS protein the 
OD for wells with no antigen. All blockers except gelatin were diluted in phosphate 
buffered saline. Gelatin was diluted in carbonate buffer. Blotto = 1% powdered 
milk, 1% Triton XlOO, 50 mM Tris HCl (pH 8.5), 0.05% Tween 20, and 10 mM 
EDTA in PBS. Superblock is a proprietary solution from Pierce (Rockford, IL). 
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Incubation times 
ELISAs with 60 minute incubations had slightly higher signal to background 
ratios than 30 minute incubations (table 2). An incubation period of 45 minutes (for 
all antigen-antibody and blocking steps) was chosen as a reasonable compromise 
between maximum detection of antigens and practical time limits. 
Table 2: The effect of varying incubation time on detection of p26. 
Recombinant Gag3 BlV-infected FBL 
cell supernatants 
Incubation Time 0.50 /ig/ml 0.25 f ig/ml 
30 minutes 9.3* 6.3 3.1 
60 minutes 11.2 6.6 3.1 
'Signal/background ratio (the OD reading for wells with antigen divided by the OD 
for wells with no antigen). 
Detection methods : TMB, ABTS, and OPD substrates 
Three different horseradish peroxidase ELISA substrates were tested: TMB 
(3,3'I5,5'- Tetramethylbenzidine dihydrochloride), ABTS (2,2*-Azino-di-(3-ethyl-
benzthiazoline-6-sulfonate)) and OPD (o-Phenylenediamine). Table 3 shows the 
results of an experiment comparing TMB and ABTS substrates. Although the 
signal/background ratios for TMB and ABTS are similar, the actual OD values for 
TMB were 5 times higher than for ABTS and it was, therefore, easier to detect 
positive samples with TMB. TMB was more sensitive than OPD; the signal to 
background ration for 2.5 ;^g/ml recombinant Gag protein was 1.5 times higher for 
TMB than for OPD. 
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Table 3: The signal/background ratios for ABTS and TMB ELISA substrates, for 
several antigen sources. 
Recombinant Gag3 BlV-infected FBL 
cell supematants 
Substrate 2.5 Atg/ml 0.25 A^g/ml 0.025 ^tg/ml 
ABTS 6.3' 2.5 1.1 1.1 
TMB 6.9 2.6 1.1 LI 
Signal/ background ratio = the OD reading for wells with antigen divided by the 
OD for wells with no antigen. 
Specificity for BIVp26 - cross-reactivity with other retroviruses 
The reactivity of several other retroviruses was tested in the ELISA assay 
(Table 4). The viruses tested include equine infectious anemia (EIA), bovine 
leukenvia virus (BLV), and bovine syncytial virus (BSV). The EIA virus tested was a 
stock solution of the MA-1 clone. The source for the BLV virus was culture 
supematants of FLK-BLV persistently infected cells (provided by J.A. Miller). Both 
of these antigen solutions were cell supematants, and contained virus concentrations 
much higher than are expected to be present in supematants from BIV infected 
cells. Both viruses showed veiy slight reactivity in the p26 assay. The BSV vims 
antigen was a cmde lysate of bovine embryonic spleen cells, used in the agar gel 
immunodiffusion (AGID) assay for BSV (provided by M.J. Van der Maaten); this 
particulate solution appeared to bind readily and non-specifically to surfaces. 
Therefore, the reactivity of the BSV antigen in the p26 assay may have been due to 
non-specific binding. 
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Table 4: Detection of other retroviruses by the BIV p26 ELISA. 
Antigen OD Antigen OD 
Recombinant BIV Gag3 2.1 Equine infectious 0.16 
0.2S anemia virus 
None 0.11 Bovine leukemia virus* 0.21 
Bovine syncytial virus 
1:4 0.20 
1:40 0.14 
1:400 0.13 
'Bovine leukemia virus is a cell supernatant from FLK-BLV cell cultures; these 
cultures are co-infected with bovine leukemia virus and non-cytopathic bovine virus 
diarrhea virus. Equine infectious anemia virus is a stock solution of the MA-1 clone. 
BSV antigen is a lysate from BSV infected bovine embryonic spleen cells. 
Results of p26 detection in macrophage supematants 
Although BIV p26 antigen could be detected in infected FBL cell 
supematants, p26 was barely detectable or not detected in supematants of 
macrophage cultures from infected animals (Table 5). Samples of macrophage 
supematants examined on other dates were consistent with these results. No p26 
antigen was detected in supematants collected from macrophage cultures of 3 
control, 4 BlV-infected, 5 BLV-infected, and 5 BIV/ BLV co-infected cattle. 
Macrophage supematants from different treatment groups were not found to be 
significantly different from each other; furthermore, values were not significantly 
different from background (no antigen) levels. Some macrophage cultures were 
stimulated with LPS at 4 /xg/ml; these supematants also did not contain detectable 
p26. 
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Table S: Detection of p26 in selected macrophage and FBL cell supematants. 
Sample OD 
Recombinant Gag3 - 0.25 /xg/ml 2.05 
No antigen 0.11 
BlV-infected FBL cell supematants 
Virus from animal #808 
11/25/92 culture 0.56 
11/26/92 culture 0.50 
Virus from animal #342 
11/25/92 culture 0.38 
11/26/92 culture 0.45 
Macrophage cultures from BIV infected animals 
Animal #356 (control) 0.11 
Animal #808 (BIV infected) 0.15 
Animal #341 (BIV infected) 0.12 
Conclusions 
Although the p26 capture ELISA does appear to detect recombinant BIV 
p26 antigens, its use for detecting p26 in cell supematants appears to be limited. 
The ELISA could detect p26 in BlV-infected FBL cell culture supematants; 
however, detection was marginal in some samples. Furthermore, this assay does not 
appear to be useful in the system for which it was developed. Although the assay 
was developed to detect p26 in infected macrophage cultures, levels of p26 appear 
to be very low in supematants from these cells. Other evidence, including the 
inability to detect reverse transcriptase activity in macrophage cultures (data not 
shown), as well as the evidence that BIV is spread in bovine macrophage cultures 
mainly through cell contact (Appendix C), support the hypothesis that little vims (or 
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viral protein) is released into macrophage supematants. The sensitivity of this assay 
(detection limit approximately 0.025 /xg/ml) could possibly be improved by 
purification of the antibodies used; however, this project was not pursued, due to 
the likelihood that p26 levels in macrophage supematants would be difficult to 
detect, even with improved sensitivity of the assay. 
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